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Abstract 
Diabetes is one of the world’s greatest health related concerns, and it affects more and more 
people every year.  
The objective of this thesis was to investigate the various effects that the synthetic 
glucocorticoid dexamethasone exerted in rats. Dexamethasone in high concentration has 
been shown to induce insulin resistance in rat models, the models showing similar signs of 
disease as in patients affected by Cushing’s syndrome.  
The purpose of this thesis was to investigate how dexamethasone treatment affected 
glucose metabolism in muscles. Skeletal muscles were incubated under the influence of 
different mediators of glucose and glycogen metabolism; insulin, adrenaline and contraction. 
Two experiments were conducted; I and II.  
The purpose of Experiment I was to investigate the effects of dexamethasone treatment 
during five days of treatment. Insulin sensitivity was measured with glucose uptake and 
western blots. Glycogen content and lactate release were also measured.  
The purpose of Experiment II was to investigate the effects of dexamethasone treatment 
after eleven days, and compared how a fed and fasted state affected the dexamethasone-
induced state of insulin insensitivity. Glycogen content, western blots, lactate release and 
glucose uptake were measured.   
Experiment I and II show dexamethasone-mediated insulin insensitivity based on alterations 
in insulin-responsive tissues as skeletal muscles and liver.   
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1 Background 
1.1 Diabetes 
1.1.1 Prevalence 
The incidence of diabetes is rising in most parts of the world, WHO estimate the prevalence 
in all age groups worldwide to be 2.8 % in 2000, projected to reach 4.4 % by 2030 [1]. The 
numbers of patients with diabetes was 171 million worldwide in 2000, WHO estimates it to 
increase to 366 million in 2030 [1], while the International Diabetes Federation (IDF) is 
projecting 246 million in 2007 and 333 million in 2025 [2]. The cost of diabetes care is 
growing fast and IDF claims diabetes care is going to be a dominating contributor to most 
countries’ health budgets by the end of 2025 [2]. The American yearly expense caused by 
diabetes patients was $US132 billion in 2002 increasing to $US192 billion in 2020 [3]. 
Current approximations show that 90-120 000 patients have diabetes mellitus (DM) in 
Norway, of which 90 % type 2, many studies claim there may be just as many un-diagnosed 
patients [4]. The Norwegian Diabetes Association suggests a comparable figure of DM; 
250 000 in total, where half of these may be un-diagnosed [5]. There are few signs that this 
epidemic of diabetes and metabolic diseases will cease to develop during our life-time, 
mainly due to an aging population and a modern, sedentary lifestyle with high-energy diets. 
It is also a grave concern that the developed world progress to adopt `western´ lifestyles as 
well. 
  
 
 
“In developing countries, as their economies grow, non-communicable 
diseases will become more prevalent largely because of the adoption of 
`western´ lifestyles and their accompanying risk factors – smoking, high-
fat diets, lack of exercise” 
The World Health Report 1998, WHO 
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1.1.2 Pathophysiology 
Diabetes is a variety of conditions that manifests itself in hyperglycemia. The reasons for 
hyperglycemia are diverse and results in classification of diabetes into different sub-groups. 
The most common type of diabetes is type 2 (type 2 DM), which is also called non-insulin-
dependent diabetes mellitus (NIDDM). This is caused by lack of insulin production, reduction 
in the response of insulin (insulin resistance) or a combination of these. The other type is 
diabetes type 1 (type 1 DM, insulin-dependent diabetes mellitus, IDDM) where the auto-
immune system attacks the insulin-producing β-cells in the pancreas, and hence ceases 
insulin production in vivo.   
The focus in this thesis is type 2 DM, as dexamethasone (dex) are known to induce insulin 
resistance and mimic this type of diabetes, and not the autoimmune type 1 DM. The view of 
type 2 DM has developed in the last 30 years from being seen as a relatively mild ailment 
seen in the elderly to one of the leading causes of morbidity and mortality in most 
countries[2].  Complications from DM are micro- and macrovascular and hence one of the 
leading causes of death through its effects on cardiovascular disease (CVD) [2]. Elevated 
blood sugar levels are directly toxic and will over time lead to tissue damage (Figure 2).  
There are some intermediate steps between normoglycemia and type 2 DM as well which 
are in focus when treating diabetes. Impaired Fasting Glucose (IFG) and Impaired Glucose 
Tolerance (IGT) are two of those [3]. Consult Appendix 1 – WHO Summary of Technical 
Report and Recommendations [3] definition of these different stages.  
The research in this field shows that conditions previously considered to have different 
etiology really are related to each other, in fact this is of such importance that the term 
`metabolic syndrome´ was developed. Metabolic syndrome consists of various clinical 
findings, the criteria from WHO (2006) specifies these (Table 1) [6]. It must be noted that 
other guidelines exist as well, but these are not mentioned here.  The term `diabesity´ is also 
used to describe the clustering of symptoms found in patients at risk of type 2 DM. Energy 
intake per capita has increased from 2 300 kcal in 1 963 to 2 720 kcal in 1992 [7], this 
combined with a sedentary lifestyle and possibly psychological stress instead of physiological 
stress might all lead to higher risk of any metabolic disease.  
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Table 1: WHO diagnostic criteria for the metabolic syndrome* 
The diagnosis of metabolic syndrome require at least 3 of the 5 criteria to be met: 
Criteria Defining level 
Abdominal obesity 
- Men Waist circumference  >102 cm (>40 inches) 
- Women Waist circumference  >88 cm (>35 inches) 
High levels of triglycerides  At least 150 mg/dL 
Low HDL cholesterol 
- Men <40 mg/dL 
- Women <50 mg/dL 
High blood pressure At least 130/>85 mmHg 
High fasting glucose  At least 110 mg/dL 
*Adapted from a WHO publication (2006) [6] 
1.1.3 Diabetic risk factors 
Obesity and the hormonal dysregulation in adipose tissue are considered to be two of many 
risk factors of type 2 DM, and especially abdominal obesity [2, 8, 9]. A causal relationship 
between visceral adipose tissue aggregation and insulin resistance was established by 
Gabriely et al. [10]. Removal of adipose tissues from various anatomical sites showed 
markedly different effects on metabolic outcomes. Removal of visceral fat (peri-renal and 
peri-epididymal) from various insulin-resistant rat models markedly improved peripheral and 
hepatic insulin sensitivity and glucose tolerance[10]. High BMI correlates with increased 
cortisol excretion, however, plasma cortisol levels are usually lower in obese patients 
compared to non-obese [9]. This could be due to enhanced peripheral metabolism of 
glucocorticoids (GCs) or increased activity in the HPA axis as a result of decreased sensitivity 
to GC feedback [9]
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There is evidence that diabetics have a 
two to four times larger risk of CVD than 
the general population [2, 11]; one study 
conducted in Norway compared CVD 
mortality rates for two periods of time; 
from 1984-86 and from 1995-97. The 
study discovered a major decrease in 
mortality from CVD in the general 
population, a decrease which also 
benefited patients with diabetes, but the 
more than 2-fold higher mortality rate in 
diabetics persisted[11]. Risk factors such 
as hypertension and dyslipidemia add up 
and worsen the morbidity/mortality of 
diabetics [2]. 
 
 
 
 
 
 
 
 
 
Figure 1: Heart attacks in people with and without 
diabetes over a period of seven years; adapted from [2] 
 
Many studies show that life style and socio-economic status correlates with obesity, and 
hence increases the risk of type 2 DM [7, 12]. This effect might be due to a lot of factors; 
stressful and long hours at work, constantly having a feeling of being an `under-dog´ in 
addition to the cheap, but unhealthy, fast-food are all mentioned as plausible causes. It has 
been calculated that if a whole population avoids BMI > 25, the risk of type 2 DM will 
decrease by 65 – 76 % (in a Caucasian population that is) [7].  
Genetic predispositions is inevitably linked to many type 2 DM conditions, as well as HPA 
axis dysregulation [13]. A direct correlation between some genetic predispositions and type 
2 DM was found in the Norwegian HUNT project [14]. Specific type 2 DM-related loci were 
investigated in patients diagnosed with type 2 DM and compared to patients without the 
diagnosis. The HUNT study is the first to use a large population-based body of material, 
without any selection in patient material. Triglyceride levels, BMI, cholesterol and WHR were 
available and correlated with genotyping comparing undiagnosed and diagnosed patients 
with type 2 DM. The study concludes many SNPs related to type 2 DM, and is important to 
broaden our scope of genetic predispositions involved in the development of type 2 DM.  
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Other studies show how an adjustment of diet and exercise in risk groups can benefit the 
patients in terms of decreasing the risk of type 2 DM and associated complications. A study 
conducted in Chinese patients with IGT compared the relative risk for complications in an 
intervention group (intervention is diet and/or exercise) with a group of patients receiving 
regular treatment; the relative risk for DM in the intervention group was 38 % lower (CI 95 % 
17 to 55) than the control group after the 6 years treatment [15]. The same study also shows 
the longevity of the beneficial effects; 20 years after study closure the patients in the 
intervention group experienced a mean of 3.6 fewer years with diabetes. The most alarming 
finding was that 93 % of the patients in the control group were diagnosed with diabetes 
after 20 years, compared to 80 % in the intervention group; this emphasize the importance 
early intervention. The study did not find any significant difference in CV complications 
between the two groups. Another study with patients suffering from IGT was conducted in 
Finland [16]. The patients in this study received similar guidance in terms of exercise and diet 
as the Chinese study, but specifically focused at reducing total fat intake and saturated fat 
intake. The cumulative incidence of diabetes during the 4 years was 11 % in the intervention 
group, compared to 23 % in the control group (CI 95 %; 6-15 % vs. 17-29 % respectively). 
During the 4 years the risk of DM was decreased by 
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58 % in the intervention group. The 
authors state that data may be 
conservative since it was done on an 
`intention to treat´-basis and since the 
control group, for ethical reasons, 
received advice on lifestyle changes as 
well. The authors state that the reduction 
in diabetes incidence was directly 
associated with lifestyle changes and that 
type 2 DM can be prevented by lifestyle 
changes in high risk patients [16].  All 
these studies show how type 2 DM is 
caused by a multifaceted and intricate mix 
of many factors, and most of all; the 
disease is preventable in many of the 
cases if treated early.  
 
Figure 2: The major diabetic complications [2] 
 
 
The importance of a closely monitored blood glucose level as well as monitoring of HbA1c is 
critical; results from the UK Prospective Diabetes Study (UKPDS) show that patients treated 
intensively differ in HbA1c  levels compared to the conventionally treated group; the 
intensively treated group had a mean HbA1c 0.9 % lower than the conventionally treated 
group[17]. This resulted in a reduction in risk of any diabetes-related endpoint (12 %), 
diabetes-related death (10 %) and a reduction in all-cause mortality (6 %) during the study 
period of 10 years. The risk reduction of any diabetes-related endpoint was mainly due to a 
25 % reduction in microvascular endpoints.  Contradictory to this, a recent study published 
in NEJM (12th June 2008) showed an increase in mortality and weight gain in an intensively 
treated patient group (reached an HbA1c of 6.4 %) compared to the control group (reached 
an HbA1c of 7.5 %) [18]. An implication of increased mortality in this study led to an early 
abortion after 3.5 years due to ethical reasons.  
It must be noted that patients in the UKPDS study only received either sulfonylureas or 
insulin, while patients in the American study received various classes of antidiabetics and a 
combination of these. This might in part be an explanation of the contradictory results. The 
15 
 
American study highlights the hypoglycemic events and its effect on mortality ratios. The 
study also describes the importance of a controlled and reasonable drug regimen.   
1.1.4 Treatment 
Diabetes has existed as an untreatable disease in all times, first described by the ancient 
Egyptians. A treatment for type 1 DM arose in 1921 as the hormone named insulin was 
discovered. Administration of insulin itself has changed from human to porcine or bovine 
insulin harvested from pancreas and then to synthetic insulin with altered qualities in terms 
of initiation and duration of effect, stability and reduction in risk of immune reactions. The 
availability of oral treatments for type 2 DM has also developed; the sulfonylureas, 
developed in the 50’s, were the first oral treatment to arise. The introduction of the 
biguanids, thiazolidindiones and the alpha-glucosidase inhibitor came next. A new class of 
antidiabetica emerged recently as the two (as per May 2009) substances related to a gut 
hormone was developed and termed incretine mimetics. It is easy to forget the benefits one 
can achieve by changing lifestyle (i.e. diet, exercise) in patients with type 2 DM, especially 
from a pharmaceutical point of view given all the new drugs on the market. One might soon 
see a change where the aim of type 2 DM therapy is not the treatment of clinical findings but 
the prevention of such in risk groups through lifestyle changes.  
1.1.5 Drug-induced hyperglycemia 
It is well known that many drugs interfere with the metabolic pathways, and hence change 
glucose concentrations in blood. Many of the most commonly used drugs in Norway today 
can increase blood concentrations to such an extent that diabetics can experience difficulties 
controlling their disease [19, 20]. Many articles are discussing the most used drugs, and their 
risk of hyperglycemia, the two articles from B Luna and M N Feinglos [19] and M Pandit et al 
[20] presents many concerns. The two groups most interesting for this thesis is the effect of 
β-blockers and glucocorticoids (GCs), which are both two of the most commonly prescribed 
groups of drugs in Norway; a search in the Norwegian Prescription Database from the 
Norwegian Institute of Public Health [21] using search criteria; ATC-code C07 (β-blockers) 
found a prevalence of use in 2007 to be 72.98/1,000 inhabitants, while a search on ATC-code 
H02 (GCs for systemic use) found a prevalence of use in 2007 to be 35.99/1,000 inhabitants. 
It is important to note that the patients getting these drugs on a daily basis often suffer from 
other diseases as well, increasing the risk of diabetes development over time. A recent 
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prospective cohort evaluated the increased risk of DM after initiation of a β-blocker or a 
thiazide diuretic [22]. The results show a vastly increased risk of DM after the 6-year follow-
up; 28 % increased risk of developing DM in subjects receiving β-blocker therapy, the data 
are independent of the degree of hypertension or family history of type 2 DM. The pro-
diabetic effect of GCs has been known for decades; first showed by Long et al. in 1940, and 
recent evidence show that insulin resistance occur both at pre- and post-receptor sites [20]. 
It is also shown that GCs as hydrocortisone, prednisone and prednisolone are more 
diabetogenic than other GCs used, due to molecular differences. Prednisolone is the most 
frequent orally administered GC in Norway, its share of the total DDD in ATC-code H02 was 
approximately 81.9 % in 2007 (ca 16,71 out of a total of 20.39 million DDD) [21].  
1.2 Glucose and glycogen; metabolism 
Glucose is stored as glycogen in all vertebrates and the regulation of the metabolism of 
these substances is intricate [23]. Excess glucose is stored in a polymeric form as glycogen; 
and can in itself represent up to 10 % and 1-2 % of liver and muscle weight respectively [24]. 
To relieve the cells from the shear osmotic pressure of the vast amounts of glucose stored, a 
polymer is formed in large cytosolic granules to form an α-rosette. Glycogen itself is 
synthesized from glucose-6-phosphate via glucose-1-phosphate and UDP-glucose. Under 
conditions of insulin stimulation, the majority of muscle glucose cleared by the skeletal 
muscle are incorporated into glycogen [25]. It is showed that nearly 35 % of carbohydrates in 
a meal are stored as muscle glycogen, 20 % as liver glycogen [24]. Skeletal muscles cannot 
release glucose molecules as they lack glucose 6-phosphatase, hence muscles or adipocytes 
are prone to contribute glucose in a situation of e.g. fasting through other means, such as 
lactate release for instance [24]. Glycogen can be broken down as a response to adrenaline 
activation of cAMP dependent protein kinase (PKA) and the following amplification, or due 
to Ca2+ or adenosine monophosphate (AMP) (due to vigorously contractions) activation of 
protein kinase B (PKB/Akt), both leading to activation of glycogen phosphorylase (GP) and 
glycolysis. These reactions are allosteric and take place in the passing of milliseconds. 
Hormones as insulin, glucagon (too high or too low levels of blood glucose, respectively) and 
adrenaline (`fight or flight´ hormone) are somewhat slower in mediation of effect and takes 
place in the passing of seconds or minutes. 
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It is said that this glycolysis in myocytes probably is mediated through glycogen-bound 
phosphatase, particularly phosphatase 1 (PP1) [26]. If sufficient oxygen is present, the end 
product pyruvate will be fully oxidized in the mitochondria to H2O and CO2. At high intensity 
or if insufficient levels of oxygen are present pyruvate is converted to lactate, and the 
majority of lactate is released in the blood [24]. Lactate in the blood stream is available as an 
energy source for other tissues (e.g. heart tissue) once released or function as precursors for 
gluconeogenesis in liver or the kidneys [24]. 
The catabolic pathway from glycogen is catalyzed by GP, while the anabolic pathway to 
glycogen is catalyzed by Glycogen Synthase (GS) [23, 27]. The glycogen molecule is bound in 
a complex with GS, GP and several other enzymes that regulate the synthesis and 
metabolization of glycogen [25, 27, 28]. Glucose uptake and GS are the rate-limiting steps in 
glycogen synthesis in skeletal muscles [29], and regulation of these are of interest. The 
glucose-6-phosphate activates GS allosterically, however to achieve full activation GS 
demands covalent phosphorylation at some of nine different serine residues [24, 30, 31]. 
Although the inverse relationship between glycogen concentration and GS activity is well 
established (first by Danforth et al. 1965 [32]), the mechanisms of GS regulation needs 
further elucidation[28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 
33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33][28, 33]. 
Glycogen content strongly regulated GS activity [25, 27, 28, 32, 33], and has even been 
shown to regulate GS fractional activity to a higher extent than insulin[30]. Contraction also 
strongly influences GS activity, it has been reported that contraction reduces GS Ser641 and 
Ser645,649,653,657 phosphorylation, but the exact pathway is elusive. It has been suggested that 
this activation is mediated through lower glycogen content as contraction leads to this, 
however, a recent experiment suggest this not to be the case and that contraction regulates 
GS activity independently of glycogen content [30]. It has been shown that Ser641 and Ser645 
are the two most important serine residues responsible for GS activation [29]. These two 
residues are mainly phosphorylated by GSK-3 as discussed in the next section.  
1.3 Insulin signaling 
Insulin binding to the insulin receptor (IR) leads to spontaneous auto-tyrosine-
phosphorylation – the first step in the phosphorylation cascade following binding of insulin 
[34]. The IR can itself be phosphorylated and hence deactivated by regulatory proteins such 
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as tyrosine phosphatases [35]. Another protein important to mention in this context is the 
suppressor of cytokine signaling-1 (SOCS1), which has been seen to be upregulated in states 
of insulin resistance such as obesity [35]. Insulin receptor substrate – 1 (IRS-1) is then 
phosphorylated, amongst various other substrates, and binds the regulatory subunit of 
phosphatidylinositol 3-kinase (PI 3-kinase). The regulatory subunit is p85 α, while the 
catalytic subunit is p110. Both of these subunits have a protein module known as Src 
homology (SH2) domains that interact with the phosphotyrosine-part of IRS-1. It is through 
PI 3-kinase activation that recruitment of PI 3-kinase to signaling complexes adjacent to 
membranes takes place [12, 31, 34, 36]. The p110 subunit of PI 3-kinase is responsible for 
the activation of PIP2 to PIP3 in the plasma membrane. PIP3 is a second messenger that 
mediates critical regulation of insulin signaling in the cell [35]. Hence PI 3-kinase is 
responsible for modulation of several proteins through PIP3 activation; perhaps the most 
essential being through PDK-1 mediation. PDK-1 phosphorylates the PKB Thr308 residue and 
enhancing its activity [31, 35], however, PKB must be phosphorylated at Ser473 for full 
activation. This is mediated through what was previously called PDK2; mammalian target of 
rapamycin (mTOR) complexed with the rapamycin-insensitive companion of mTOR (RICTOR) 
[37]. When PKB is phosphorylated at both residues, the enzyme exhibits a 4- to 5-fold higher 
activity compared to Thr308 alone [38]. PKB is found in three different isoforms, the PKBα is 
the isoform responding to insulin in muscles and in liver [31], PKBβ being the second one to 
be found in skeletal muscles. PKB will when activated phosphorylate GSK-3 (GSK-3 α at Ser21, 
and GSK-3 β at Ser9), deactivating the GSK-3 kinase and hence decreasing its activity towards 
GS [31, 35, 36]. Impaired GSK-3 effect promotes the active de-phosphorylated version of GS 
and an increase in glycogen synthesis [35]. GSK-3 β is more important than GSK-3 α in 
regulation of GS in skeletal muscles [39]. The activity of GS is, as previously discussed, 
regulated by glucose-6-phosphate and phosphorylation at nine different serine residues, in 
which GSK-3 is the single most important regulator of [34, 36].  
There are many different isoforms of the GLUT transporter, but in skeletal muscles two exist; 
the GLUT1, which is omnipresent, and GLUT4, which is restricted to insulin-sensitive tissues 
[40]. Insulin recruits GLUT4 from intracellular vesicles, in which ≈90 % of the transporters are 
stored in the basal state [41]. The GLUT4 is recruited to the cell membrane; this mechanism 
is thought to be the major mechanism responsible for insulin-mediated glucose uptake [34, 
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36, 40-42]. 70-90 % of glucose taken up in the myocytes following insulin stimulation is 
incorporated into muscle glycogen [24].  Insulin and contraction are the two most important 
inducers of glucose uptake in skeletal muscles [25, 43]. PKB stimulates GLUT4 translocation 
to the cell membrane [31, 36], hence increasing glucose uptake [28]. This is mediated 
through PKB’s phosphorylation of Akt Substrate 160 kDa (AS160); a Rb GTPase activating 
protein [24, 29, 31, 44]. 
Figure 3: Insulin signaling pathway through the PKB pathway and its regulation of glucose uptake [35]. The three 
AKT/protein kinase B (PKB) isoforms (in red) share the same structural organization: a pleckstrin-homology (PH) domain, 
which is required for binding to phospholipids, and a catalytic domain (Cat), which becomes active on phosphorylation (P) 
of two residues (Tyr308 and Ser473 for AKT1, Tyr309 and Ser474 for AKT2, and either Tyr305 alone or Tyr305 and Ser472 
for AKT3). The upstream regulators of AKT/PKB activity are represented in green. Positive regulators are 
phosphatidylinositol 3-kinase (PI3K), which produces phosphatidylinositol-3,4,5-triphosphate (PIP3) in response to insulin. 
PIP3 recruits phosphoinositide-dependent kinase-1 (PDK1) and AKT/PKB at the plasma membrane, where AKT/PKB is 
phosphorylated by PDK1 and PDK2 (this is thought to be a complex between the mammalian target of rapamycin (mTOR) 
and the rapamycin-insensitive companion of mTOR (rictor)). Negative regulators include the phosphatases phosphatase and 
tensin homologue (PTEN), Src-homology-2 domain-containing inositol phosphatase-2 (SHIP2), phosphatase-2A (PP2A) and 
the PH-domain leucine-rich-repeat protein phosphatase (PHLPP). Tribbles-3 (TRB3) is another protein that can bind to and 
inhibit AKT/PKB. The downstream targets of AKT/PKB are shown in purple. The GTPase activating protein AKT substrate of 
160 kDa (AS160) is one of the AKT/PKB targets that is responsible for the translocation of the glucose transporter-4 
(GLUT4). Glycogen synthase kinase-3 (GSK3), forkhead box O1 (FOXO1) and the tuberous sclerosis complex-1 and -2 
(TSC1/2) complex are direct targets of AKT/PKB. GSK3 inhibits glycogen synthase (GS). Phosphorylated FOXO1 is 
sequestered in the cytoplasm on binding to 14-3-3 proteins. TSC1/2 inhibits the small GTPase Ras homologue enriched in 
brain (Rheb), an activator of mTOR. mTOR, associated with regulatory associated protein of mTOR (raptor), phosphorylates 
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its substrates eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and p70 ribosomal protein S6 kinase 
(p70S6K). Plain arrows represent an activation process, and blocked arrows represent an inhibition process. IR, insulin 
receptor; PEPCK, phosphoenolpyruvate carboxykinase. 
1.4 Stress hormones  
1.4.1 Anatomy 
Stress as a definition is easy to understand and surrounds us in our day to day life. 
Psychological stress versus physiological stress will affect the body’s hormone balance, 
through the HPA axis (Hypothalamic-pituitary-adrenal axis) or SAM system (symphatetic-
adrenomedullary) as explained later [45]. Stress perceived as either threatening or 
challenging has shown to induce different responses in humans. Threat stress will induce a 
reaction from the HPA axis (GC release), compared to challenging stress which induce the 
SAM system (catecholamine release) [45]. Stress in rats seem to act differently than in 
humans; rats are almost always prone to eat less (but not in cases where the rats are given a 
diet rich in fat) while 30 % of humans are prone to eat less, while the rest are prone to eat 
more [45].  
Adrenal GC secretion is normally controlled by the HPA axis, striving homeostasis, and 
occasionally also from ACTH-independent mechanisms (Adrenocorticotropic hormone; also 
known as corticotropin)[8]. Corticotropin-releasing hormone (CRH) initiates the stress 
response in the HPA axis and is the most important regulator as it stimulates release of 
ACTH, which in turn stimulates steroid release; cortisol or corticosterone in mammals and 
rodents respectively [8]. Consult Figure 4 for a better view of the pathway in regulation of 
GC production. The adrenal cortex synthesize and secretes the GCs, while the adrenal 
medulla produces catecholamines (adrenaline and noradrenaline), and several 
neuropeptides [8]. The secretion of catecholamines is mediated through activation of the 
sympathetic nervous system as well as through ACTH mechanisms.  
21 
 
Figure 4: Adrenal gland steroids and their respective actions, adapted after Roberge et al. [8] 
1.4.2 Glucocorticoids 
The understanding of GCs in this already intricate puzzle of the metabolic syndrome and 
stress is built upon the studies of Cushing’s syndrome – sustained elevation of cortisol 
secretion [8, 34, 46]. The acute effect of GCs is described as one of the `fight and flight´ 
responses is responsible for many homeostatic actions; liberation of fuel through effects on 
glucose and fatty acid metabolism, shock protection through effects on haemodynamics and 
fluid balance and effect on acute immune responses through anti-inflammatory action [45, 
46]. It is clear that the effects of GCs are vital for humans to adapt to stress, although these 
effects are only of benefit if transient. Sustained elevated levels of GCs will lead to symptoms 
seen in Cushing’s syndrome; central obesity, hypertension, glucose intolerance and 
dyslipidemia [8, 9, 46]. GCs in general oppose insulin action [9, 47] and causes insulin 
resistance [34, 36]; they mediate adipose tissue differentiation, function and distribution, 
and in excess causes visceral obesity [12]. GCs also have a direct inhibitory effect on glucose-
induced insulin release from the pancreatic β-cells[41]. The combination of high GC levels, 
dense calories and in turn elevated insulin contributes to this visceral fat distribution [45]. 
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 A Swedish research group studied the regulation of GC levels in humans in relation to 
somatic symptoms. GC levels were tightly regulated, with an efficient feedback mechanism 
in healthy subjects – making them able to respond to everyday stress [13]. Contrary to this 
group was a group not able to control their GC levels tightly and experienced consistent mal-
secretion; the group introduced the term `hypothalamic arousal syndrome´ and described a 
parallel activation of both the HPA axis and the SAM system. There was found correlating 
somatic symptoms to `hypothalamic arousal syndrome´: inhibited secretion of sex steroids 
and growth hormone, insulin resistance, abdominal obesity, elevated leptin levels, 
hyperglycemia, dyslipidemia and hypertension with elevated heart rate [13]. The findings 
suggest the syndrome is responsible for many of the metabolic symptoms, caused by 
environmental factors and genetic predispositions. Many studies point at GC dysregulation 
as one of the key issues understanding pathophysiology in diabetes and metabolic syndrome 
[8, 12, 45, 46]. Skeletal muscles and the liver are organs are both insulin- and GC-responsive, 
and hence crucial organs in regulation of adipose tissue, as well as obesity and diabetes 
[9].GCs enhance glucose production in the liver both directly by transactivating crucial genes 
involved in the process and indirectly by stimulation of other hormones, e.g. glucagon [9]. 
On the other hand, insulin opposes GC action through decrease of GC receptor expression in 
skeletal muscle [9]. 
GC metabolites in adipose tissue, colon and kidneys are recycled by the enzyme 11β-
hydroxysteroid dehydrogenase Type 1 (11β-HSD1) through conversion from cortisone to 
cortisol. This specific enzyme has thus been connected to the development of obesity and 
insulin resistance [9, 48, 49], as shown in Figure 5. Excess of GCs have shown to lead to 
growth of visceral adipose tissue, and hence an evil circle where more adipose tissue seem 
to develop as the local recycling of GC is increased. The action of the two 11β-HSDs, type 1 
and 2, is mainly in insulin-responsive central adipose tissue and in the kidneys respectively 
[46]. The reason why visceral adipose tissues are linked to diabetes, compared to how 
subcutaneous adipose tissues are not, might be due to the higher responsiveness and sheer 
number of GC receptors. 
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GCs enhancement of 11β-HSD1 expression 
happens to a higher degree in visceral 
adipose tissue than normal tissue [8, 9, 
46]. In addition to this Roberge et al. 
points out that since the GC recycling may 
be of similar amplitude as the original GC 
secretion, as well as the recycled 
hormones have direct access to the liver 
via the portal vein [8].  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Interconversion of cortisone to cortisol, 
catalyzed by 11β-HSD1 [9, 46] 
 
1.4.3 Synthetic cortisone; dexamethasone 
Dex is a synthetic GC and is more potent than cortisol, though not exerting any 
mineralcorticoid properties. The substance is frequently used in animal models, and has 
been shown to inhibit insulin-stimulated glucose transport in rats at a concentration of 1.0 
mg/kg [50]. This concentration is based on the secretion found in adult male humans; which 
under normal conditions is 0.2 mg/kg, but during stress can increase 10-fold to 2.0 mg/kg 
[51]. Qi et al. have proven insulin resistance after 4 hours of dex treatment using the 
euglycemic-hyperinsulinemic clamp method in rat [50, 51]. Literature show that the time 
span for which dex is given normally is 4-12 days when investigating dex’s effect on glucose 
metabolism, consult Appendix 8 for a list of experiments using dex treatment (page ). 
Experiments at STAMI has previously conducted dex treatment for 12 days [36] and 11 days 
[34].  
One of the clinical effects of dex treatment in high doses is growth retardation, dex treated 
rats are expected to either lose or slowly gain weight as this is reported in several 
publications. A large weight difference can introduce bias to the data for many reasons, rats 
with more adipose tissue can exhibit other metabolic responses compared to lean rats. 
There is especially seen that larger rats exhibit lower insulin sensitivity as they grow larger, 
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while the dex treated rats are leaner. Consult the tables below for the weight differences 
experienced in some published studies. Dimitriadis et al. found that proteolysis in muscle 
arose after 5 days dex treatment, thus increasing alanine-levels. The increased amount of 
alanine leads to increased turnover via the alanine-cycle, producing lactate, then yielding 
pyruvate [42] that potentially affects results as it will convert to glucose. Dimitriadis et al. 
discuss the clinical relevance of this to be low, especially since the buffer used for incubation 
contains 2 mM of pyruvate. 
Table 2: Average rat weight, Ruzzin et. al(Control n=29, 
dex n=28)[36].  
 Day 12* 
Control 321.9 ±5.0 g 
Dex (1.0 mg/kg) 233.4 ±3.2 g 
* Significant weight-difference between the two groups, p 
<0.006. 
 
Table 3: Average rat weight, Coderre, L., et al. 
(n=10)[26].  
 Day 1 Day 7 
Control 201 ± 2 g 236 ± 2 g 
Dex (1.0 mg/kg) 209 ± 2 g  154* ± 2 g 
* Significant weight-difference between the two groups, 
p<0.001 
Table 4: Average rat weight, Coderre, L., et al. (n=10)[40].  
 Day 1 Day 7 
Control 201 ± 2 g 240 ± 3 g 
Dex (0.4 mg/kg) 198 ± 2 g  185* ± 4 g 
Dex (1.0 mg/kg) 211 ± 3 g  154* ± 1 g 
* Significant weight-difference between the two groups, p<0.001 
 
1.4.4  Adrenaline 
Activation through the SAM system increases secretion of catecholamines, one of these are 
adrenaline. Glucose uptake is regulated by adrenaline but, unlike muscle contraction and 
insulin, it is seen as the single most important inhibitor of glucose uptake [43]. Studies 
showing adrenaline-mediated inhibition of insulin-stimulated glucose clearance in vivo [43] 
and inhibition of insulin-stimulated glucose uptake in skeletal muscles [25] support this.  
Adrenaline activates GP and stimulates glycolysis [24] via β-adrenoceptors, this is especially 
evident in type II (fast-twitch) muscles such as Epi and EDL [25]. In type I muscles (slow-
twitch), that normally have a lower glycogen content, adrenaline have minimal ability to 
stimulate glycogen breakdown [25]. The phosphorylation cascade downstream of β-
adrenoceptors is described shortly; adrenaline binding to these receptors release cAMP, 
hence activating PKA and glycogen phosphorylase kinase [25, 52]. Glycogen phosphorylase 
kinase phosphorylates GP b and transforms it to the active a form [25]. GS is also 
phosphorylated by adrenergic stimulation, this will hence inactivate the enzyme and start 
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glycogen breakdown [27, 52]. It has also been shown that while most of GP is 
phosphorylated to the active form during adrenergic stimulation in fast-twitch muscles, this 
is not the case in slow-twitch muscles – although the latter muscles inhibit a β-adrenoceptor 
density almost twice as high as in fast-twitch muscles [27].  
There is a cross-link between PKB phosphorylation and adrenaline-stimulated cAMP release 
as well, this cross-link is called Epac. Epac is a GTPase exchange factor activating Rap1, and 
there is growing evidence that cAMP-mediated PKB activation requires the presence of Epac 
[52]. Brennesvik et al. showed additive effect on PKB phosphorylation of insulin and 
adrenaline supporting this [52].  
1.5 The role of skeletal muscles in glucose homeostasis 
Insulin is not the only factor in the crucial task of glucose uptake. Contractile activity is along 
with insulin the two most important stimuli of glucose uptake [25, 43] through GLUT4 
translocation [53]. Contractile activity mediate GLUT4 translocation through a pathway 
different from insulin; contraction activates AMP-activated kinase (AMPK) independent of PI 
3-kinase [24]. Skeletal muscles are important in the regulation of blood glucose levels, and 
many claim emerging insulin resistance in skeletal muscles is one of the major causes of type 
2 DM development [26, 40]. Skeletal tissue comprises up to 40 % of body weight in an adult 
human being, and is responsible for 70-90 % of insulin-stimulated glucose uptake. This 
glucose is mainly stored as muscle glycogen [28]. The continuous metabolism and catabolism 
of glycogen is closely regulated, the metabolism through GS and GP are the major 
contributors to this homeostasis [27].  
Muscle fibers have been divided into type I and II through histochemical staining of the 
fiber’s ATPase activity; acid-stable and alkali-labile type I (slow-twitch) and acid-labile and 
alkali-stable type II (fast-twitch). Type II fibers is then again divided into type IIA and IIB [54]. 
Both type IIA and IIB contract more rapidly, but type IIB is fatigued at an earlier stage than 
type IIA. Type I fibers contract more slowly, and are fatigued less readily than type IIA and 
IIB. The contractile property of a muscle depends on what fibers the muscle is constituted of 
[54] (Table 5). T Nakatani et al. indicate that fibers of a high-oxidative nature (fast-twitch 
muscles) has a higher degree of mitochondrial activity compared to fibers of less oxidative 
activity [54].  
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Different muscle fiber types have different roles; hence the muscles dissected out in these 
experiments performed at STAMI are expected to give somewhat different results. The two 
pieces obtained from one sol results in two relatively similar muscles both in size and 
composition (mainly slow-twitch)[54]), while the two EDLs are somewhat different from 
each other; one white (superficial part of muscle) that has a higher majority of type II fibers 
while the other one (red, deep part of muscle) has a higher majority of type I fibers[54] 
(Table 5). The two muscle strips are consistently differed between and referred to as 
respectively rEDL and wEDL. The epi muscle, is fast-twitch and contains mostly of type II 
fibers [25].  
Table 5: Specifications of various fiber types and muscles, presented in % (mean ± SEM) [27, 54, 55] 
 
 Type I (slow-twitch) Type IIA (fast-twitch) Type IIB (fast-twitch) 
wEDL (superficial)  0 11.2 ± 4.1 88.8 ± 4.1 
rEDL (deep)  10.0 ± 3.1 26.7 ± 6.9 63.3 ± 8.5 
Soleus 87 13 0 
Epitrochlearis [56] 10-15.0 15-23 67-70 
Glycogen content Low High High 
Oxidative capacity High High Low 
Mitochondrial density High High Low 
  
Fibers increasingly more readily fatigued 
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2 Purpose 
2.1 Experiment I 
The purpose of Experiment I was to investigate the onset of dex-mediated effects.  
The following questions were tested: 
1) How will dex treatment affect glycogen content? 
a. In skeletal muscle 
b. In liver 
c. In cardiac muscle 
2) How will dex treatment affect activation of the insulin signaling pathways? 
3) How will dex treatment affect insulin-stimulated glucose uptake in skeletal muscles? 
2.2 Experiment II 
The purpose of Experiment II was to investigate the dex-mediated effects after 1 and 11 
days. Another purpose was to compare the effect of fasting (24 hours) 
The following questions were tested: 
1) How will dex treatment affect glycogen content? 
a. In skeletal muscle 
b. In liver 
2) How will dex treatment affect the rate of lactate release? 
3) How will dex treatment affect activation of the insulin signaling pathways? 
4) How will dex treatment affect the efficiency of different mediators on glucose uptake 
in skeletal muscle? 
5) How will fasting for 24 hours differ from fed status, and how will fasting status affect 
purposes 2-5? 
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3 Methods and materials 
3.1 Rats 
Male Wistar rats (Bk1:Wist) from B & K Universal AS (Nittedal, Norway) were used in all 
experiments. The rats were kept in our laboratory animal facilities for at least a week prior to 
experiment. Room temperature was kept at 21 °C, humidity was kept at 55 %, and a 12:12 
hour light/dark cycle (from 6 AM to 6 PM) was obtained throughout the housing. The rats 
had free access to standard rat chow (B & K Universal, Grimston UK) and tap water. The 
experiments were performed during the light cycle (between 10 AM and 3 PM). The rats 
were all treated with either dex (1.0 mg/kg, dissolved in saline) or saline (9 mg/kg) by 
intraperitoneal injection (i.p.) at 10 AM. Experiments and procedures were approved by 
official authorities and performed in accordance with the laws and regulations controlling 
experiments on live animals in Norway and the European Convention for the Protection of 
Vertebrate Animals used in Experimental and Other Scientific Purposes.  
3.2 Muscle preparation and incubation 
Muscles where prepared and handled as described earlier in articles by Jensen et al. [28, 34, 
43]. All rats were anesthetized with an IP injection of ≈ 10 mg of pentobarbital sodium (50 
mg/ml) per 100 g rat. Epitrochlearis (epi), soleus (sol) and extensor digitorium longus (EDL) 
were dissected first. The epi were studied intact, while sol and EDL were both split in two; 
sol resulting in two relatively homogenous muscles, while EDL was split in wEDL and rEDL. 
The sol is cut with a scalpel, while the EDL is split by tearing along the tendons stretching to 
each toe. The muscles were mounted at their approximate resting length on electrodes, 
consult Figure 8. The electrodes were placed in test tubes with 3.5 ml buffer and gassed 
continuously (95 % O2, 5 % CO2) throughout incubation, as well as at least 15 minutes before 
mounting. All incubation was conducted in a water bed (30 °C). After preincubation (30 
minutes, 3.5 ml Krebs-Henseleit buffer), the electrodes were taken out and placed in vials 
with the radioactive buffers, consult flow charts presented below. The muscles were 
removed from the electrodes after incubation (½ hour and 1 hour in Experiment I and II 
respectively), blotted on filter paper to remove excess buffer and frozen in liquid N2. 
Incubation buffer was saved in experiment II for lactate analysis. Muscles were cut in cryo-
stat before analysis (-20 °C), samples for western blot were weighed (ww) and frozen (-70 
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°C), while samples for glucose uptake and glycogen content were freeze dried (3 hours), 
weighed (dw) and frozen (-70 °C). 
 
Figure 6: Flowchart of Experiment I 
 
 
Figure 7: Flowchart of Experiment II 
 
Figure 8: Schematic presentation of the electrodes used and test tube (left), mounted epi muscle (right) 
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3.3 Muscle contraction 
Some of the muscles were contracted isometrically in the basal buffer. The muscles were 
stimulated with impulse trains of 200 ms at a frequency of 100 Hz (square wave pulses of 0.2 
ms duration and 10 V amplitude) delivered at a rate of one train per 2 s for 60 minutes in 
experiment II.  
3.4 Statistics 
All data sets were entered into Word Excel standard sheets prepared by Jorid Thrane 
Stuenæs for the respective methods. All p-values in Experiment I was found using Word 
Excel formulas; due to a small test size unpaired student’s t-test assuming unequal variance 
were performed. All figures are prepared using SigmaPlot version 10.0. 
Experiment II has a bigger test size and analyses of variances (ANOVA) were used, as well as 
a least significant difference (LSD) post hoc test. The software used to perform these 
analyses was SPSS 16.0. Unpaired student’s t-test assuming equal variance was performed to 
compare responses on day 1 versus day 11 using Word Excel formulas.  
P-values were acknowledged with an alpha significance level =0.05. p-values > 0.05 were 
termed as `borderline´ significant and discussed where appropriate.  
3.5 Glucose uptake analysis 
Glucose uptake was conducted as described in articles from J. Jensen et al. [28, 43]. In brief 
0.25 µCi/ml 2-[1,23H(N)]deoxy-D-glucose (30.6 Ci/mmol; NET 549 PerkinElmer) and 0.1 
µCi/ml D -[1-14C]mannitol (54.5 mCi/mmol; NEC 314 PerkinElmer) were added to the Krebs-
Henseleit buffer and counted for radioactivity (d.p.m, Tri-Carb 1900 TR, Packard). A freeze-
dried muscle sample (2-3 mg dw) was dissolved in 600 µl 1 M KOH for 20 minutes at 70 °C, 
samples were mixed several times. Samples were cooled and centrifuged (3000 G, 10 
minutes). Blanks were prepared and handled together with the samples; 2 vials 600 µl 1 M 
KOH and 2 vials 600 µl 1 M KOH with 50 mM glycogen control solution (Seronorm 20 µl, 
precipitated in 500 µl 0.4 M perchloric acid). 400 µl of the homogenate/blanks and 3 ml 
Hionic Fluor scintillation cocktail (Hionic-Fluor 6013319, Perkin-Elmer) were pipetted into 
counting tubes (Pony Vial 6000292, PerkinElmer) and then counted for radioactivity; two 
different pre-programmed settings count the two isotopes in 2 cycles x 5 minutes.  
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Background for analysis of glucose uptake 
Some assumptions were made; similar uptake kinetics for glucose and 2-3H-deoxyglucose 
(DG) during incubation, hence the relation between glucose- and 2-3H-DG -uptake was equal 
to the relation between the concentrations of the two in the incubation buffer. The amounts 
of radio-marked glucose analogues were assumed equal in the extracellular compartments 
as in the incubation buffer, and 14C mannitol was assumed not to be subject to transport into 
the cells. Since the amount of 2-3H-DG added, dw and specific activity of the buffer are 
known, the uptake of 2-3H-DG can be calculated. Glucose uptake is equal to 2-3H-DG -uptake 
multiplied by the concentration relationship between glucose and 2-3H-DG in the incubation 
buffer.  
3.6 Glycogen content analysis; muscles 
The method for measurement of glycogen content in muscle follows what is described by 
Aslesen et al. [43]. 100 µl of the muscle homogenate/controls from the dissolution in KOH 
was hydrolyzed by amyloglucosidase (Amylase, AmG), in this case a γ-amylase that 
hydrolyzes glycogen. 100 µl of muscle homogenate/controls were pH-adjusted to 4.8 using 
20-25 µl 7 M acetic acid and 500 µl 0.3 M acetate buffer (with AmG, 30 µg/ml). 
Homogenate/blanks were mixed and incubated for 3 hours at 37 °C. Reaction solution were 
made daily and kept on ice, composition of which is presented in `Appendix 5´, page 86. 25 
µl sample/blanks are pipetted into acid-washed vials (10 x 75 mm) together with 750 µl 
reaction solution and mixed. Glycogen contents were measured on Shimadzu 
spectrofluorophotometer RF-5000 (which delivers valid results in the fluorescence area 0.5 – 
10 µM), and all solutions were kept at a stable temperature of 23-25 °C during counting. 
Background emission were measured first; then added 5 µl hexokinase and mixed. Glycogen 
contents in the vials were measured as Δ fluorescence after 20-30 minutes.  
Background for analysis of glycogen content;  
1) glycogen  amyloglucosidase >  glucose 
2) glucose + ATP  hexokinase >  glucose-6-phosphate + ADP 
3) glucose-6-P + NADP+  G6PDH >   6-P-gluconolacton + NADPH + H+ 
Glucose is being phosphorylated in reaction 2) to glucose-6-phosphate that is oxidized by 
NADP+ in reaction 3). Reaction 3) is heavily skewed to the right, hence levels of reacted 
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glucose is proportional with levels of NADPH made. NADPH is measured as the increase in 
fluorescence after addition of Hexokinase, wavelengths 340 nm (excitation) and 460 nm 
(emission).  
3.7 Glycogen content analysis; liver and heart 
Direct acid hydrolysis was used to dissolve the freeze-dried liver and heart (1-2 mg dw) in 
respectively 3000 and 1000 µl 1M HCl for 2.5 hours at 100 °C, and mixed several times. 
Samples were cooled, and centrifuged (3000 G, 10 minutes). Blanks were prepared and 
handled together with the samples; 2 vials 1 M HCl, and 2 vials 1 M HCl/ 50 mM glycogen 
control solution (Seronorm 20 µl, precipitated in 500 µl 0.4 M perchloric acid). Samples were 
cooled and centrifuged 2 vials of 1M HCl and 2 vials of 1M HCl were added 30 µl glycogen 
standard solution (Seronorm 20 µl, precipitated in 500 µl 0.4 M perchloric acid). 100 µl of 
liver samples were diluted in 300 µl 1M HCl, heart samples were not. Reaction solution were 
made daily and kept on ice, composition of which is presented in `Appendix 5´ on page 86. 
10 µl sample/blanks were pipetted into acid-washed vials (10 x 75 mm) together with 750 µl 
reaction solution. Glycogen contents were measured on Shimadzu spectrofluorophotometer 
RF-5000 (which delivers valid results in the fluorescens area 0.5 – 10 µM), and all solutions 
were kept at a stable temperature of 23-25 °C during counting. Background emission was 
measured first, then added 5 µl hexokinase and mixed. Glycogen contents in the vials were 
measured as Δ fluorescence after 20-30 minutes.     
3.8 Glycolytic flux 
Glycolytic flux measurements were conducted in several pilot experiments, the method is 
added in `Appendix 6´, page 88. This method is not described closer as no results from these 
pilot studies are presented in this thesis due to failure to provide certain results. This 
method would be interesting as it would provide information of to what extent glycogen 
would undergo glycolysis and in addition make it possible to conduct measurements of 
glycogen synthesis in the same samples.  
3.9 Glycogen synthesis 14C and 3H 
The method used at STAMI for measurement of glycogen synthesis is usually including 14C-
glucose as the radioactive compound. However, to be able to measure glycogen synthesis 
and glycolytic flux in the same samples, a series of pilot studies was done to compare results 
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in glycogen synthesis between the two radioactive substances. Our pilot studies did not find 
equal findings when comparing glycogen synthesis with 14C and 3H and was hence 
abandoned.  This method is not described closer as no results from these pilot experiments 
are presented in this thesis. A detailed description of this method is provided in `Appendix 
7´, page 89. 
3.10 Lactate release in buffer 
The method for measurement of lactate in muscles was adapted to measure lactate release 
in incubation buffer. It was crucial that all electrodes, vials and equipment used were 
washed in H20millipore. Lactate levels in sweat are many times higher than in blood, thus clean 
equipment and latex gloves were crucial. In addition vials with electrodes (but without 
muscles) were incubated (30 °C) for 1-2 hours together with the vials containing muscles to 
be used as blanks. After incubation, and freezing of the muscles in liquid N2, the buffer was 
kept on ice (for as short time as possible) until it was pipetted into vials and frozen (-20 °C).  
Reaction solution were made daily and kept on ice, composition of which is presented in 
`Appendix 5 ´ page 86. 10 µl sample/blanks were pipetted into acid-washed vials (10 x 75 
mm) together with 750 µl reaction solution. 2 blanks containing 10 µl 10 mM L(+)-lactate 
(Sigma L-1750) were prepared as parallels. Lactate concentration was measured on 
Shimadzu spectrofluorophotometer RF-5000, and samples were kept at a stable 
temperature of 23-25 °C during measurement. Background emission was measured first; 
then added 5 µl 10 U/ml LDH and mixed. Lactate release were measured as Δ fluorescence 
after 45-60 minutes. 
Background for analysis of lactate release;  
1) L-(+)-lactate + NAD+  lactate dehydrogenase (LDH) >  pyruvate + NADH + H+ 
2) pyruvate + glutamate  glut-pyr-transaminase (GPT) >  alanine + a-ketoglutarate 
Lactate is oxidized by NAD+ in 1). To ensure the reaction is skewed to fulfillment towards 
NADH, pyruvate is removed from the solution in the reaction catalyzed by addition of 
glutamate and GPT (both added in abundance), as well as ensuring basic environment. It is 
crucial to sustain as high a pH as possible, without induction of denaturation. The production 
of NADH is measured as an increase in fluorescence, which is directly proportional to lactate 
release in the samples. The wavelengths measured are at 340 nm (excitation) and 460 nm 
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(emission). The method is specific for L-(+)-lactate, as the enzyme LDH is not reacting with D-
(-)-lactate.  
3.11 Western blot 
A sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) method was used 
to do western blotting, all solutions used are declared in `Appendix 5 ´ on page 86. 
3.11.1 Homogenization of muscle samples 
Muscles for homogenization were weighed (ww, ≈10 mg) in -20 °C. Homogenization buffer 
was made the same day and added to the vial containing the muscle (ratio 1:30). The muscle 
was homogenized immediately, 2 x 15 seconds (Polytron PT1200, +4 °C). 1 % Triton X-100 
was added after homogenization and the samples rotated in +4 °C for 1 hour. Samples were 
centrifuged (10 minutes, +4 °C, 11,500 g) and the supernatant was pipetted and the volume 
measured with an electronic pipette. 30 µl of the supernatant was diluted in 200 µl 
H2Omillipore. The method measuring total protein levels follows the instruction manual of DC 
Protein Assay (Bio-Rad laboratories). DC Protein Assay reagents was added and transferred 
to plastic cyvettes for determination of Optical Density (OD) at 750 nm in a 
spectrophotometer (Shimadzu MPS-2000). Additional buffer based on the results from the 
total protein assay was added to the samples to a uniform protein concentration (in the 
range 1.0 - 2.5 µg/µl). 100 µl of the homogenates with equal protein concentration were 
added to a solution of 6.2 µl 2-mercapto ethanol and 25 µl 5xSDS. The samples were left in 
room temperature for at least 2 hours, then frozen until used (-20 °C).  
3.11.2 Gel making 
Western blot is a method used for a semi-quantitative measurement of protein expression 
and phosphorylation with the help of antibodies. The proteins are in this method (SDS-PAGE) 
denatured and divided via electrophoresis, depending on molecular weight. The gel used in 
this method is an SDS-polyacrylamide gel consisting of a stacking gel (top, 4 %) and a 
separation gel (bottom, 10 %). The stacking gel will concentrate the added sample volume 
(10 – 14 µl); concentrating the solution, and narrowing the bands. The function of SDS is to 
destroy secondary and tertiary protein structure through breakage of disulfide bonds, and 
cover the proteins giving the proteins a uniform negative charge. The only factor separating 
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the proteins will hence be the size as SDS makes the charge:mass ratio even in all proteins. 
All equipment used is from BioRad (Model no. Mini-PROTEAN® 3 Cell).  
3.11.3 Electrophoresis 
Samples were mixed gently after defrost, and applied to the gels’ 15 wells. A marker was 
added to visually indicate protein bands with specified molecular weight. The amount of 
sample added was 10-14 µl. The electrophoresis was run on 4 gels at a time, and the 
electrophoresis buffer filled the chamber in which the gels were placed. Voltage of 100 V 
was added to the system to compress the samples in the stacking gel (10 minutes) then 
increased to 180 V (70 minutes total).  
3.11.4 Blotting 
This method uses polyvinylidene fluoride (PVDF) membranes. The transmission of proteins 
from the gel to the membrane (blotting) is based on hydrophobic interactions as well as 
charged binding between membrane and protein. The membranes are equilibrated in 100 % 
methanol for 15 seconds, water for 5 minutes and transfer buffer for at least 15 minutes, the 
gels are added to the transfer buffer together with the membranes (minimum 10 minutes). 
A blotting sandwich was made, consisting of; filter pad, filter paper x 2, gel, membrane, filter 
paper x 2 and filter pad. It was important to remove excess air from between the layers 
before blotting. Blotting was commenced in cold blotting buffer with constant stirring with a 
constant power of 250 mA added to the system for 1 hour.  
3.11.5 Blocking and immune reactions with antibodies 
The membranes were washed 3x10 minutes in PBS/0.1 % Tween-20 (PBS-T). Blocking of the 
membranes in 5 % skimmed milk (Tine unspecified dry milk) dissolved in PBS-T, for 2 hours in 
room temperature was done to reduce unspecific binding of the antibodies. The membranes 
were washed in PBS-T for 2x30 seconds after blocking, and then incubated in the primary 
antibody. The primary antibody was added in a solution of 3 % BSA in PBS-T, the primary 
antibody was used several times (stored in -20 °C). A complete list of all antibodies used 
presented in `Appendix 5´ (page 85). All these antibodies require overnight incubation in +4 
°C with constant motion, then washing (6 x 10 minutes in PBS-T). The secondary antibodies 
(1 % BSA, PBS-T) were made the same day, at least 15 minutes prior to use. The membranes 
were incubated for 1 hour in room temperature, and washed (6 x 10 minutes in PBS-T). 
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3.11.6 Exposure, interpretation 
PBS-T buffer from the washing were carefully dried off and ECL (Enhanced 
Chemiluminescent)-liquid was applied to the membranes for 5 minutes. Membranes were 
carefully dried and put in a plastic folder on a Teflon plate. ECL detection uses the enzyme 
Horseradish peroxidase (HRP) which catalyzes the oxidation of luminol by peroxide. Oxidized 
luminol emits light when returning to its stable state. The HRP enzyme is connected to a 
secondary antibody; hence the enzyme will only adhere to bands on the membrane where 
the secondary antibody is attached to a primary antibody. The reaction is called Horseradish 
peroxidase chemiluminescent reaction.  
The protein bands were detected in Fuji las 4000 mini and interpreted (as OD) in the 
software provided by the manufacturer (Multi Gauge). Data is processed in Windows Excel. 
The background of each band was subtracted from the OD. Samples from saline treated 
insulin-incubated muscles were used as comparison for all the other groups; the values of 
the other samples are calculated as % of these values. This was to be able to make 
comparisons between the different gels. 
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4 Results 
4.1 Experiment I 
Consult `Time-course Experiment I´, page 83 for further information regarding the 
experiment. The muscles studied in this experiment were the sol and epi muscles, 3 and 2 
harvested per rat respectively. The heart and liver were also analyzed.                                                                                                                                                                                                                                                                                                                                                                                                                                        
4.2 Rat and muscle weight  
The weight of dex treated rats are lower than the saline treated rats after 5 days treatment 
with a difference between the groups of ≈20 grams (p<0.04) (Table 6). There were no 
differences in weight between saline and dex treated rat muscles during this experiment 
(Table 7). 
Table 6: Mean rat weight on the day of experiment, (n=4).  
Treatment Day 1 Day 2 Day 3* Day 5* 
Saline 165.3 ±7.9 g 168.5 ±3.5 g 173.8 ±8.7 g 186.8 ±9.0 g 
Dex (1.0 mg/kg) 161.8 ±4.6 g 159.0 ±9.4 g 159.3 ±7.4 g 166.5 ±12.6 g 
*Significant weight-difference between the two groups, P <0.05 and <0.04 respectively 
 
Table 7: Mean muscle weight on the day of experiment 
Treatment Muscle Day 1 Day 2 Day 3 Day 5 
Saline Epi (n=8) 28.4 ± 1.9 mg 28.4 ± 1.6 mg 28.3 ± 1.2 mg 33.9 ± 1.8 mg 
Sol (n=11-12) 29.6 ± 1.9 mg 31.7 ± 1.6 mg 36.8 ±1.4 mg 34.0 ± 1.9 mg 
Dex  Epi (n=8) 27.6 ± 1.1 mg 29.7 ± 2.2 mg 27.0 ± 1.8 mg 32.6 ± 1.4 mg 
Sol (n=11-12) 30.7 ± 1.1 mg 31.0 ± 1.5 mg 32.4 ± 1.6 mg 32.9 ± 1.5 mg 
No significant difference between saline and dex treated muscles 
4.3 Glycogen content – epi and sol 
Glycogen contents in epi (Figure 9) are higher in dex than saline treated groups on days 2, 3 
and 5 (p<0.02). There is no significant difference in glycogen content on day 1. 
Dex’s effect on glycogen content in skeletal muscles was strengthened as time progressed: 
glycogen content in epi was approximately 30 % higher in dex versus saline treated rats on 
day 1, but ≈55 % higher on day 5 (p<0.02). 
Glycogen contents in sol (Figure 10) are higher in dex than saline treated groups on days 2, 3 
and 5 (p<0.03). Glycogen content is not significantly higher in dex compared to saline treated 
groups on day 1.  Glycogen content was ≈10 % higher in dex versus saline treated rats on day 
1, but ≈60 % higher on day 5 (p<0.03). 
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Figure 9: Effect of dex treatment on glycogen content in epi.                     
Epi from saline and dex treated rats (open and filled bars respectively). Treatment was given for 1-5 days, and rats were 
fasted 12 hours prior to experiment. Muscles were incubated for 30 minutes without insulin.           
Data are presented as means ± SEM, n=4. *p<0.02. 
 
 
 
 
 
 
 
 
 
Figure 10: Effect of dex treatment on glycogen content in sol.                 
Sol from saline and dex treated rats (open and filled bars respectively). Treatment was given for 1-5 days, and rats were 
fasted 12 hours prior to experiment. Muscles were incubated for 30 minutes without insulin.         
Data are presented as means ± SEM, n=3-4, *p<0.03. 
39 
 
4.4 Glycogen content - liver and heart 
Liver from saline treated rats shows nearly complete depletion of glycogen storages after 12 
hours fast (average glycogen content ≈25 mmol/kg) (Figure 11). Liver glycogen content in 
dex treated shows no such depletion compared to the saline treated rats (average glycogen 
content ≈530 mmol/kg). Liver glycogen content in dex treated rats are higher than saline 
treated rats (p<0.03 on day 1, 2 and 5; p<0.06 on day 2).  
Average liver weight is stable in saline treated rats, while it increases in dex treated groups 
from day 1 to 5. Keep in mind that dex rats weighed approximately 20 g less than control 
rats on day 5, yet some of the dex treated rats had a liver twice as heavy as the control rats.  
 
The heart glycogen content (Figure 12) on day 1 is higher in dex treated compared to saline 
treated rats (p<0.02), as well as on day 5 (p<0.06). Heart glycogen tended to be higher in dex 
than saline treated rats on days 2 and 3 as well, though not significantly higher. 
  
40 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Effect of dex treatment on liver weight and glycogen content.              
Liver from saline and dex treated rats. Treatment given for 1-5 days, rats fasted 12 hours prior to experiment. Mean 
weights of the livers are plotted as lines. Bars are presented as means ± SEM, n=4. *p<0.03, 
(
*
)
p<0.06. 
 
 
 
 
 
 
 
 
 
 
Figure 12: Effect of dex treatment on glycogen content in heart.                
Heart from saline and dex treated rats (open and filled bars respectively). Treatment given for 1-5 days, and rats fasted 12 
hours prior to experiment. Data are presented as means ± SEM, n=3-4. *p<0.02, 
(
*
)
p<0.06. 
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4.5 Western blots 
4.5.1 PKB Ser473 phosphorylation 
The blots show decreased insulin-stimulated phosphorylation of PKB Ser473 in dex treated 
compared to saline treated groups (Figure 13, and blots in Figure 16). The decrease in dex 
treated insulin-stimulated phosphorylation at Ser473 is ≈25 % on day 5 (p<0.03), and ≈50 % 
on day 1 (p<0.14). Muscles incubated in basal buffer show a trend of higher basal 
phosphorylation of PKB Ser473 when comparing saline to dex treated groups. The PKB Ser473 
phosphorylation in all basal groups is less than 15 % of the insulin-stimulated saline treated 
group.  
 
Figure 13: Effect of dex treatment on PKB Ser
473
 phosphorylation:                                                       
Epi from saline and dex treated rats (open and filled bars respectively). Treatment was given for 1 or 5 days, rats were 
fasted 12 hours prior to experiment. Level of phosphorylation is calculated as % of the insulin-incubated muscles from 
saline treated rats. Data are presented as means ± SEM, n=3-4 in insulin groups, n=2-3 in basal groups. *p<0.03, 
(
*
)
p<0.14. 
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4.5.2 PKB Thr308 phosphorylation 
The western blots of PKB Thr308 phosphorylation (Figure 14 and blots in Figure 16) coincides 
with the western blots of PKB Ser473 phosphorylation (Figure 13).  
The blots show significantly decreased insulin-stimulated phosphorylation of PKB Thr308 in 
dex treated compared to saline treated rats on both day 1 and day 5 (p<0.04), the reduction 
from saline-treated muscles being ≈50 and ≈30 % respectively. Muscles incubated in basal 
buffer show a trend of higher basal PKB Thr308 phosphorylation in saline treated compared 
to dex treated groups, but the phosphorylation in all these groups are less than 15 % of the 
insulin-stimulated saline treated group.  
 
Figure 14: Effect of dex treatment on PKB Thr
308 
phosphorylation:               
Epi from saline and dex treated rats (open and filled bars respectively). Treatment was given for 1 or 5 days, rats were 
fasted 12 hours prior to experiment. Level of phosphorylation is calculated as % of the insulin-incubated muscles from 
saline treated rats. Data are presented as means ± SEM, n=3-4 in insulin groups, n=2-3 in basal groups. *p<0.04, 
(
*
)
p<0.12. 
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4.5.3 GSK-3β Ser9 phosphorylation 
The blots of insulin-stimulated GSK-3β Ser9 phosphorylation show no significant differences 
when comparing dex and saline treated groups (Figure 15 and blots in Figure 16). Insulin-
stimulated GSK-3β Ser9 phosphorylation shows a tendency to have decreased from day 1 to 
day 5 in the dex treated group compared to the saline treated groups, the decrease is ≈ 15 
%. Muscles incubated in basal buffer show a trend of higher basal phosphorylation in the 
saline than the dex treated groups, especially on day 5.  
 
Figure 15: Effect of dex treatment on GSK-3β Ser
9 
phosphorylation:                 
Epi from saline and dex treated rats (open and filled bars respectively). Treatment given for 1 and 5 days, rats fasted 12 
hours prior to experiment. Level of phosphorylation is calculated as % of the insulin-incubated muscles from saline treated 
rats. Data are presented as means ± SEM, n=3-4 in insulin groups, n=2-3 in basal groups  
 Day 1 Day5 
Insulin            +           +             -              -             +              +             -           - 
Dex            -            +             -             +             -               +             -           + 
PKB Ser473    
PKB Thr308   
GSK-3β Ser9   
GSK Total 
protein 
  
Figure 16: Blots showing phosphorylation levels for the PKB Ser
473
, PKB Thr
308
, GSK-3 Ser
9
 and GSK total protein 
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4.6 Glucose uptake – epi and sol 
Glucose uptake in dex treated epi groups are lower compared to the saline treated groups 
(Figure 17). Dex treated rats had a significantly lower glucose uptake on day 5 compared to 
saline treated groups when incubated in basal buffer (≈70 % lower, p<0.05) but not 
significant when incubated in supraphysiological insulin buffer (10,000 µU/ml)(≈35 % lower, 
p<0.20).  
The dex treated sol show significantly lower basal glucose uptake on day 3 compared to the 
saline treated group (p<0.04) (Figure 18). The dex treated group shows no significant 
difference in basal glucose uptake on day 5, but glucose uptake is ≈35 % lower compared to 
the saline treated group. Dex treatment showed lower level of insulin-stimulated glucose 
uptake (200 µU/ml) than saline treatment on days 1, 2 and 5 (p<0.10 in all groups, glucose 
uptake ≈55 % lower on day 5). Dex treatment showed lower level of insulin-stimulated 
glucose uptake (10,000 µU/ml) than saline treatment on day 5 compared to the saline 
treated group (p<0.09, glucose uptake ≈40 % lower).  
Glucose uptake decreases from day to day, even in the saline treated muscles, but the 
decrease in glucose uptake from day 1 to 5 is only significant in the insulin-stimulated  
muscles (10,000 µU/ml)(Table 8). 
Table 8: % change in glucose uptake from day 1 to day5 in the respective groups,  p-values 
Sol Basal Ins 200 µU/ml Ins 10,000 µU/ml 
Saline treated -50 %,p<0.12 -25 %, p<0.25 -25 %, p<0.28 
Dex treated -50 %, p<0.20 -35 %, p<0.30 -40 %, p<0.04* 
Epi Basal  Ins 10,000 µU/ml 
Saline treated -25 %, p<0.36  -40 %, p<0.03* 
Dex treated -55 %, p<0.20  -55 %, p<0.01* 
*p<0.05 = significant 
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Figure 17: Effect of dex treatment on basal and insulin-stimulated glucose uptake in epi:                                                 
Epi from saline and dex treated rats (open and filled bars respectively). Treatment given for 1-5 days, and rats fasted 12 
hours prior to experiment. Incubated in basal buffer and insulin buffer (10,000 µU/ml) for 30 minutes. Data are presented 
as means ± SEM, n=4. *p<0.05. 
Figure 18: Effect of dex treatment on basal and insulin-stimulated glucose uptake in sol:                                                                      
Sol from saline and dex treated rats (open and filled bars respectively). Treatment given for 1-5 days, and rats fasted 12 
hours prior to experiment. Incubated in basal buffer, physiological and supraphysiological insulin buffer (200 and 10,000 
µU/ml respectively) for 30 minutes. Data are presented as means ± SEM, n=4. *p<0.04, 
(
*
)
p<0.10.  
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4.7 Experiment II 
Consult the `Time-course Experiment II´, page 84 for further information regarding the 
specifics of the experiment. Two rEDL and wEDL were harvested per rat respectively, in 
addition to the liver.  
4.8 Rat and muscle weight and ratios 
The weight and food intake in the saline and dex treated rats were measured for a period of 
14 days, and the rat weight was higher in saline treated than dex treated rats after 1 day of 
treatment (p<0.005) (Figure 19). Saline treated rats gained a mean of 35 ± 1.8 % during the 
11-days treatment, dex treated rats lost 15 ± 2.1 % of total body weight in the same period.  
Food intake in saline treated rats had a slight increase during the 14 days of measurement 
from 20 to 25 grams of food consumed daily per rat. Food intake in dex treated rats followed 
the same pattern as seen in saline treated rats before injection started with a daily food 
intake of 20 grams but dropped instantly when dex was administered (Figure 19C and D), 
equaling a ≈40 % drop in food intake on day 1. The `food intake:100 g body weight´ ratio 
show the sudden drop in food intake due to dex treatment, and then normalization of the 
dex treated group on day 7 and onwards (Figure 20).
Saline treated rats show a ≈40.0 % increase in EDL weight from day 1 to day 11. Dex treated 
rats on the other hand show a ≈5.5 % decrease in EDL weight from day 1 to 11 (Table 9).  
EDL muscle (mg):rat weight (g) ratio is presented for the different groups (Table 10). Ratios 
between dex and saline treated rats are equal on day 1, and higher in the fasted groups. 
Ratios in dex treated rats are higher than saline treated rats on day 11, and higher in the 
fasted groups. 
Table 9: Mean EDL muscle weight on the day of experiment (mg) (n=7 rats in each group) 
 Fed Fasted 
 Saline Dex Saline Dex 
Day 1 40.58 ± 3.7 33.55 ± 3.9 33.44 ± 1.1 32.63 ± 1.0 
Day 11 51.84 ± 0.8 32.56 ±1.6 49.66 ± 1.9 30.06 ± 1.8 
Table 10: Mean EDL `muscle (mg):rat weight (g)´ ratios on the day of experiment (n=7 rats in each group) 
 Fed Fasted 
 Saline Dex Saline Dex 
Day 1 0.21 0.21 0.22 0.22 
Day 11 0.22 0.23 0.23 0.24 
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Figure 19: Effect of dex treatment on rat weight and food intake.               
Rat weight and food intake in saline and dex treated male Wistar rats. Treatment was given either 1 or 11 days, rats were 
either fasted or given free access to chow ad libitum for 24 hours prior to experiment. A; Rat weights during 1 day of 
treatment, injection administered at day 0. B; Rat weights during 11 days of treatment, injection administered at day 0 and 
onwards. C; Food intake per rat, 1 day of treatment. D; Food intake per rat, 11 days of treatment. *p<0.005 between dex 
and saline treatment from this day. 
 
Figure 20: Effect of dex treatment on `food 
intake:100 g body weight´ ratio.   
`Food intake:100 g body weight´ ratio in 
saline and dex treated male Wistar rats. Rats 
were either fasted or given free access to 
chow ad libitum for 24 hours prior to 
experiment. P<0.03 from day 3-6.  
  
* 
* 
* * * 
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4.9 Glycogen content rEDL 
Figure 21: Effect of dex treatment on glycogen content in contracted and insulin-incubated rEDL:            
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour. Data are means ± SEM, n=7. *p<0.02. Lines indicate significantly higher glycogen 
content in insulin-incubated than contracted groups *p<0.007. 
Fasting decreased glycogen levels compared to the fed status by ≈ 40 % in the insulin-
incubated saline treated muscles on both day 1 (p<0.004) and day 11 (p<0.003).  
Fasting did not decrease glycogen levels to the same degree in insulin-incubated dex as in 
saline treated muscles. Fasting decreased glycogen levels in dex treated muscles by 15 % on 
both day 1 and 11 (non-significant). 
Contraction decreased the glycogen contents similar levels (60-100 mmol/kg) in all 
treatment groups on all days in the rEDL.  
Contraction decreased the glycogen content by ≈ 50 % when compared to basal glycogen 
content in wEDL (Figure 22). Glycogen content in insulin-incubated saline and dex treated 
muscles was not different from basal glycogen content in wEDL.  
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4.10 Glycogen content wEDL 
Figure 22: Effect of dex treatment on glycogen content in basal- and adrenaline-incubated wEDL:            
wEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either incubated in a basal or an adrenaline 
buffer (10
-3
 mg/ml) for 1 hour. Data are means ± SEM, n=7.*p<0.04, 
(
*
)
p<0.10. Lines indicate significantly higher glycogen 
content in basal than adrenaline-incubated groups *p<0.02, 
(
*
)
p<0.10. 
Fed basal glycogen content in wEDL has a mean of ≈200 mmol/kg in the saline treated 
muscles. Fed basal glycogen content in dex treated muscles had a mean of ≈240 mmol/kg, 
≈20 % higher than what was found in saline treated muscles (p<0.10 on day 1, p<0.02 on day 
11).  
Fasting reduced the basal glycogen content from the fed state; in saline treated muscles the 
reduction from the fed state was ≈40 % on day 1 (p<0.0005), while only by ≈10 % on day 11 
(p<0.4). This indicates less effect of fasting on day 11 than on day 1. In dex treated muscles 
the reduction from the fed state was ≈20 % on both day 1 (p<0.008) and day 11 (p<0.031).  
Adrenaline-incubation markedly decreased glycogen levels from basal levels, this effect was 
more pronounced on day 1 than day 11 as the lines show (Figure 22). Adrenaline led to a 
mean decrease in glycogen content of 25 % compared to the basal glycogen content across 
all groups.  
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4.11 Glycogen content liver 
Figure 23: Effect of dex on liver glycogen content.              
Liver from saline or dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 24 
hours prior to experiment of given free access to chow ad libitum. Data are meand ± SEM. *p<0.0005, 
(
*
)
p<0.12. 
Fed liver glycogen content was similar in dex and saline treated groups. Fed liver glycogen 
levels were lower in dex than saline treated groups on both day 1 (≈5 % lower) and on day 
11 (≈15 % lower, p<0.12).  
Fasted liver glycogen content in saline treated groups was depleted on both day 1 and day 
11 (<20 mmol/kg on both days). Fasted liver glycogen content was higher in dex than saline 
treated rats on both day 1 (≈300 mmol/kg) and day 11 (≈650 mmol/kg) (p<0.0005 on both 
days).  
The difference in liver weight is only different between saline and dex treated rats on day 11 
in the fed status (p<0.001). Only the livers from saline treated rats increase in weight from 
day 1 to day 11 (p<0.03 in both fed and fasted status). Livers from dex treated rats did not 
increase in weight from day 1 to day 11.  
Table 11: Effect of dex treatment on liver weight (n=7). 
 Fed Fasted 
 Saline Dex Saline Dex 
Day 1 8.01 ± 0.2 g 8.46 ± 0.2 g 6.14 ± 0.6 g 6.11 ± 0.4 g 
Day 11 11.13 ± 0.2 g 8.49 ± 0.6 g 7.89 ± 0.5 g 7.06 ± 0.4 g 
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4.12 Lactate rEDL  
Figure 24: Effect of dex treatment on lactate release from contracted and insulin-incubated rEDL:                     
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour. Data are means ± SEM, n=7. *p<0.006. Lines indicate significantly higher lactate 
release in contracted than insulin-incubated groups *p<0.001. 
Contraction increased lactate release from rEDL 3-fold compared to basal lactate release 
from wEDL (≈11 in saline, ≈14 mmol/kg in dex treated groups). Contraction-stimulated 
lactate release from dex treated rEDL was ≈50 mmol/kg, which was higher than saline 
treated rEDL of ≈30 mmol/kg (p<0.006).  
 
Insulin-stimulated lactate release from rEDL was somewhat similar with basal lactate release 
in wEDL. Insulin-stimulated lactate release from dex treated rEDL was ≈15 mmol/kg, which 
was higher than lactate release from saline treated rEDL ≈12 mmol/kg (non-significant).  
  
Fasting decreased contraction-stimulated lactate release by ≈25 % in the saline treated 
groups on day 1 and 11 (p<0.05 in both groups), and by 15 % in the dex treated groups on 
day 1 and 11 (p<0.008 on day 1, non-significant on day 11).  
Fasting did not alter insulin-stimulated lactate release in any of the groups 
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4.13 Lactate wEDL 
Figure 25: Effect of dex treatment on lactate release in basal- and adrenaline-incubated wEDL:                          
wEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either incubated in a basal or an adrenaline 
buffer (10
-3
 mg/ml) for 1 hour. Data are means ± SEM, n=7. *p<0.05, 
(
*
)
p<0.08. Lines indicate significantly higher lactate 
release in adrenaline-incubated than basal groups. 
Basal lactate release in saline treated groups was ≈11 mmol/kg in saline treated muscles and 
≈14 mmol/kg in dex treated groups. Overall dex basal lactate release was ≈20 % higher than 
in saline treated groups.  
Adrenaline increased lactate release from basal lactate release in a stronger manner on day 
11 compared to day 1; mean increase across all adrenaline stimulated groups were ≈45 % on 
day 1 versus ≈95 % increase on day 11. Adrenaline increased lactate release with a mean of ≈ 
70 % across all groups when compared to basal lactate release (p<0.05). 
The adrenaline-incubated lactate release was increased by fasting, the mean increase from 
basal lactate release was almost twice as high when fasted compared to fed; mean increase 
in fed was ≈50 %, while mean increase in fasted was ≈90 %.  
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4.14 Western blots 
The western blots were conducted in the rEDL muscles; these were isometrically contracted 
and insulin-incubated. The results are based on 4-7 samples, the insulin-incubated samples 
were prioritized and results from the insulin-incubated groups are based on 6-7 samples 
while contracted groups are based on 4-6 samples.  
4.14.1 PKB Ser473 phosphorylation – rEDL 
Figure 26: Effect of dex and fasting on insulin-stimulated PKB Ser
473
 phosphorylation.           
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour. Data are means ± SEM, means are calculated as % of the insulin-stimulated PKB 
Ser
473
phosphorylation in the fed saline treated group on day 1. n=4-7 in stimulated, n=6-7 in insulin-incubated groups, 
*p<0.05, 
(
*
)
p<0.15. 
The fed dex treated groups show impaired insulin-stimulated PKB Ser473 phosphorylation on 
day 1 (p<0.05) equaling a ≈40 % decrease compared to the saline treated groups. Impaired 
insulin-stimulated PKB Ser473 phosphorylation in the dex treated muscles is also evident on 
day 11 equaling ≈30 % decrease compared to saline treated groups (p<0.15).  
Fasting increased insulin-stimulated PKB Ser473 phosphorylation in all groups compared to 
the fed groups. Saline treated groups show increased insulin-stimulated PKB Ser473 
phosphorylation of ≈12 % on day 1 and 11. The fasted dex treated groups show an increase 
in insulin-stimulated PKB Ser473 phosphorylation of ≈40 % on day 1, and ≈5 % on day 11.  
Contraction-stimulated PKB Ser473 phosphorylation is less than 12 % of the insulin-stimulated 
saline treated group on day 1. 
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4.14.2 GSK-3 Ser9 phosphorylation – rEDL 
Figure 27: Effect of dex and fasting on insulin-stimulated GSK-3 Ser
9
 phosphorylation.          
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour. Data are means ± SEM, means are calculated as % of the insulin-stimulated GSK-3 Ser
9
 
phosphorylation in the fed saline treated group on day 1. n=4-7 in stimulated, n=6-7 in insulin-incubated groups, *p<0.02, 
(
*
)
p<0.12.  Lines indicate higher levels of phosphorylation in dex treated rats. 
The level of insulin-stimulated GSK-3 Ser9 phosphorylation is similar in saline treated rats on 
all days, in both fed and fasted groups. Insulin-stimulated GSK Ser9 phosphorylation is of 
similar magnitude in dex treated rats on day 1 compared to saline treated rats.  
GSK-3 Ser9 phosphorylation levels in dex treated rats on day 11 (≈15 % in fed and 40 % in the 
fasted group compared to saline).  
Fasting status and treatment does not affect the level of contraction-stimulated GSK-3 Ser9 
phosphorylation on any of the days.  
Contraction decreases all GSK-3 Ser9 phosphorylation to ≈50 – 60 % of the insulin-stimulated 
phosphorylation in the fed saline treated group on day 1. 
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4.14.3 GS Ser641 phosphorylation – rEDL 
Figure 28: Effect of dex and fasting on insulin-stimulated GS Ser
641
 phosphorylation.          
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour.  Data are means ± SEM, means are calculated as % of the insulin-stimulated GS Ser
641
 
phosphorylation in the fed saline treated group on day 1. n=4-7 in stimulated, n=6-7 in insulin-incubated groups, *p<0.05, 
(
*
)
p<0.07. Lines indicate higher levels of phosphorylation on day 11 than day 1.  
Insulin-stimulated GS Ser641 dephosphorylation happen to the same degree in saline and dex 
treated groups on day 1 regardless of fasting status. However, insulin-stimulated GS Ser641 
dephosphorylation is impaired in both dex treated groups on day 11. This impairment is 
evident on day 11 where the magnitude of phosphorylation in the fed dex treated group is 
≈50 % higher, while the fasted dex treated group is ≈100 % higher than the saline treated 
group (p<0.05).  
Contraction-stimulated GS Ser641 dephosphorylation happen to the same degree in saline 
and dex treated groups on day 1 in the fed group. However, contraction-stimulated GS Ser641 
dephosphorylation is impaired in the fasted dex compared to the saline treated group on 
day 1 (p<0.07). The impairment of contraction-stimulated dephosphorylation is more 
evident on day 11 than day 1, where the fed dex treated group is ≈50 % higher (p<0.07) and 
the fasted group is ≈25 % higher than the saline treated group. 
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4.15 Glucose uptake rEDL  
Figure 29: Effect of dex treatment on stimulated and insulin-incubated glucose uptake in rEDL:           
rEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either isometrically contracted or insulin-
incubated (10,000 µU/ml) for 1 hour. Data are means ± SEM, n=7. *p<0.05, †p<0.001. Lines indicate higher contraction-
mediated glucose uptake than insulin-mediated in dex treated groups.  
Insulin increase glucose uptake 2-3-fold compared to the basal glucose uptake seen in wEDL 
(≈10 mmol/kg). Contraction increased glucose uptake 3-fold from the basal glucose uptake 
in wEDL.  
Insulin-stimulated glucose uptake in dex treated muscles decreased from day 1 to day 11 by 
≈25 % in the fed group (p<0.04) and ≈40 % in the fasted group (p<0.001). Insulin-stimulated 
glucose uptake also decreased in saline treated muscles from day 1 to day 11 by ≈25 % in the 
fed group and also by ≈25 % in the fasted group (p<0.02).  
Contraction-stimulated glucose uptake in dex treated muscles was slightly increased from 
day 1 to day 11. Contraction-stimulated glucose uptake in the saline treated muscles 
decreased from day 1 to day 11 by ≈20-25 % in fed and fasted group (p<0.05). 
Fasting did not alter insulin- or contraction-stimulated glucose uptake in any group.  
 
  
Fed Fasted 
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4.16 Glucose uptake wEDL 
Figure 30: Effect of dex treatment on basal and adrenaline-incubated glucose uptake in wEDL.          
wEDL from saline and dex treated male Wistar rats. Treatment was given for either 1 or 11 days, rats were either fasted for 
24 hours prior to experiment or given access to chow ad libitum. Muscles are either incubated in a basal or an adrenaline 
buffer (10
-3
 mg/ml) for 1 hour. Data are means ± SEM, n=7. *p<0.05, 
(
*
)
p<0.09. Lines indicate decreased adrenaline-
stimulated glucose uptake than basal glucose uptake.  
Basal glucose uptake in wEDL was seen to be ≈10 mmol/kg. Adrenaline decreased this 
glucose uptake to 4-9 mmol/kg, which were a 40 % reduction in the fed and 20 % reduction 
in the fasted group compared to basal levels.  
Adrenaline-stimulated glucose uptake in dex treated muscles increased in the fed group 
from day 1 to day 11 by 45 % (p<0.03), while decreased in the fasted group by 8 %. 
Adrenaline-stimulated glucose uptake in saline treated muscles decreased from day 1 to day 
11 in both the fed and fasted groups by ≈35 % (p<0.07).  
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5 Discussion 
5.1 Experiment I 
Experiment I was set up to investigate whether 5 days treatment resulted in evidence of 
insulin resistance, related previous findings at STAMI and by others in 5 to 12-day 
experiments.  
5.2 Rat weight 
Dex treatment led to weight retardation         
Experiment I show higher body weight in saline than dex treated rats after 3 and 5 days of 
treatment. It is a well-known effect of GC treatment at high concentration that weight 
retardation occurs. This weight reduction is discussed in several publications – all showing 
impaired weight gain in dex treated compared to saline treated rats [26, 34, 36, 40]. The 
weight increase in saline treated rats might lead to a substantial impairment of insulin 
sensitivity when compared to smaller dex treated rats; this is discussed by Jensen et al. and 
Burén et al. [28, 34]. There is evidence from Experiment I and other experiment at STAMI 
that epididymal fat pads of dex treated rats weigh more than those from saline treated rats, 
but are smaller in dex treated rats than saline treated rats when related to rat body weight 
[34]. Pitombo et al. shows that surgical removal of visceral fat (epididymal and perinephric 
fat pads) abolished diet-induced DM in rats [57], this is also showed by Gabrielly et al. [10]. 
This articles carries strong evidence regarding the effect of extra adipose tissue as a result of 
the heavier saline treated rats. Results in these publications suggest that weight difference 
might lead to underestimation of the degree to which dex treatment affects insulin 
sensitivity [34]. There is, however, a smaller weight difference between the two treatment 
groups after 5 days treatment compared to what is normally seen after 11 days treatment in 
other experiments. The smaller weight difference is an advantage when insulin sensitivity is 
to be measured.   
5.3 Glycogen content 
5.3.1 Glycogen content in skeletal muscle – epi and sol 
Dex treatment led to higher glycogen content in skeletal muscles    
Glycogen content was higher in dex treated epi and sol than saline treated muscles on days 
2, 3 and 5 (p<0.03). Glycogen content in epi and sol was ≈55-60 % higher in dex than saline 
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treated rats on day 5. Ruzzin et al. found glycogen levels of ≈155 and ≈200 mmol/kg in saline 
and dex treated epi respectively. The authors also found glycogen levels of ≈116 and ≈160 
mmol/kg in saline and dex treated sol respectively, though not during complete fasting; rats 
had access to 5 g chow in the 18 hours prior to the experiment [36]. 
The glycogen content in saline treated epi found in Experiment I (≈100 mmol/kg) coincides 
with publications by Jensen et al. where epi glycogen content from fasted rats (12 hours) 
was ≈100 mmol/kg [25]. Jensen et al. and Lai et al. have shown glycogen content in epi to be 
similar after both 24 and 12 hours fasting in multiple publications. All articles show glycogen 
levels of ≈100 mmol/kg [25, 28-30].  
The glycogen content in our saline treated sol in Experiment I (≈ 70 mmol/kg) coincides with 
findings previously done at STAMI, but to my knowledge no publications with 12 hour fasting 
are available. Jensen et al. refer to glycogen content in sol in a fed state as ≈100 mmol/kg 
[27], while Aslesen et al. showed ≈85 mmol/kg in a fed state [43]. 
5.3.2 Glycogen content in liver and heart 
Dex treatment abolish glycogenolysis induced by fasting in liver          
Saline treated rats depleted the liver glycogen storages (mean of ≈30 mmol/kg on days 1 to 
5) whereas the dex treated glycogen storages seemed unaffected as a response to 12 hours 
fasting (mean of ≈540 mmol/kg on days 1 to 5). Ruzzin et al. showed comparable figures in 
liver glycogen content of 182.2 mmol/kg in saline treated versus 569.2 mmol/kg in dex 
treated rats (1.0 mg dex/kg, 12 days) [36]. The higher liver glycogen content in saline treated 
rats can be explained by the limited access to food as discussed previously as well as larger 
rats were used in this experiment (280 g) [36]. 
Dex treatment led to higher cardiac glycogen content         
Dex treatment led to higher cardiac glycogen content than saline treatment on all days (days 
1-5). Dex administered one day, then followed by 12 hours fasting, led to higher cardiac 
glycogen content than in saline treated rats (≈250 versus ≈115 mmol/kg respectively, 
p<0.02). The reason for the non-significant higher cardiac glycogen levels on day 2 and 3 are 
probably linked to that there were only 3 rats in the dex treated groups on these days. There 
is a higher concentration of cardiac glycogen content in the dex treated rats on day 5  (≈230 
versus ≈125 mmol/kg respectively, p<0.06). Qi et al. administered dex (1.0 mg/kg) acutely 
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which after 4 hours led to higher cardiac glycogen levels in dex than in saline treated rats 
(≈125 versus ≈180 mmol/kg respectively) [50]. This was proven again by the same research 
team by Puthanveetil et al [51]. Ruzzin et al. found equal cardiac glycogen content after 12 
days of dex treatment, suggesting that the dex-induced elevation in cardiac glycogen 
content is only seen when dex is administered acutely [36], or that 5 g of chow in the 18 
hours prior to the experiment satisfies the energy needs, hence halting glycogenolysis. Qi et 
al. concluded that dex is capable of inducing insulin resistance and switching cardiac glucose 
disposal from oxidation to storage, likely compromising the energy production in heart – in 
the span of 4 hours [50].  
5.4 Western blots 
Dex treatment decreased insulin’s ability to phosphorylate PKB Ser473 and Thr308from day 1     
Western blots for two steps downstream of IR were tested for level of basal and insulin-
stimulated phosphorylation in epi muscles. As has been shown earlier [49], blots of PKB 
Ser473 and Thr308 phosphorylation was barely detectable in the absence of insulin in both dex 
and saline treated rats. Blots of insulin stimulated PKB Ser473 and Thr308 showed severely 
reduced phosphorylation in dex treated rats at both residues. The reduction in both Ser473 
and Thr308 were ≈50 % on day 1 and ≈25-30 % on day 5. Burén et al. report of a dex-
mediated decrease in insulin stimulated PKB Ser473 and Thr308 phosphorylation by ≈40 and ≈ 
60 % respectively compared to saline treatment. Burén et al. treats the rats for 11 days, but 
the rats are of similar weight as in Experiment I and are fasted for 12 hours. The coinciding 
decrease at both residues has also been shown by Ruzzin et al. in epi [36], the authors 
reported a dex-mediated reduction in insulin-stimulated PKB Ser473 and Thr308 
phosphorylation by ≈40 % from saline treatment.  
Experiment I shows a fast onset of dex-mediated impairment of insulin-stimulated 
phosphorylation at both PKB Ser473 and Thr308 residues.  
Dex treatment decreased insulin-mediated GSK-3β Ser9 phosphorylation after 5 days        
Phosphorylation of GSK-3 deactivates the enzyme, its single most important task being 
phosphorylation, hence deactivating the GS. High levels of GSK-3 phosphorylation can be 
related to activated GS, hence enabling it to synthesize glycogen [34].  
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Experiment I shows that insulin-stimulated and basal GSK-3β Ser9 phosphorylation in the dex 
treated groups decreased from day 1 to day 5. Both insulin-stimulated and basal GSK-3β Ser9 
phosphorylation in the saline treated groups increased from day 1 to day 5. All basal GSK-3β 
Ser9 phosphorylation were found to be between 40-60 % of insulin-stimulated 
phosphorylation level in the saline treated group on day 1.  
Burén et al. support our findings of decreased GSK-3β Ser9 phosphorylation in dex treated 
muscles. The authors suggest this after a similar experiment, but it was conducted for 11 
days. Burén shows dex treatment to decrease GSK-3β Ser9 phosphorylation by ≈20 % 
compared to saline treatment [34].  
Ruzzin et al. found decreased insulin-stimulated GSK-3β Ser9 phosphorylation in dex treated 
epi compared to saline treated epi (≈20 % decrease) [49] – the authors have previously 
found matching effects in dex treated sol muscles (≈20 % decrease) [36, 49]. Ruzzin et al. 
found basal GSK-3β phosphorylation levels to be elevated in epi compared to sol (40-50 % 
versus 10 % respectively), which matches the basal phosphorylation levels seen in 
Experiment I [49].  
 There is strong evidence that PKB is a major mediator of insulin-stimulated glucose uptake, 
and that PKB phosphorylation levels are important supplements to glucose uptake in the 
investigation of insulin insensitivity, especially when GSK-3 phosphorylation can support this 
finding. Experiment I indicates that impairment of insulin-stimulated PKB and GSK-3 
phosphorylation had taken place after only 5 days. Experiment I also suggests that the dex-
mediated impairment of insulin-stimulated PKB phosphorylation has an earlier onset than 
what is found for GSK-3.  
5.5 Glucose uptake 
Dex treatment leads to impaired glucose uptake, which is worsening day by day  
Experiment I showed a lower insulin-stimulated glucose uptake in the dex treated compared 
to the saline treated groups. Glucose uptake shows a widening gap between dex and saline 
treated muscles as the difference becomes larger and larger further into Experiment I. This 
shows that 5 days dex treatment impairs glucose uptake. The effects are not as evident in all 
muscle types, however, or at supraphysiological insulin concentrations.  
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Dex treatment led to lower basal glucose uptake in both epi and sol       
The decrease in basal glucose uptake from day 1 to day 5 was ≈35 % in both saline and dex 
treated epi muscles, and ≈50 % in both saline and dex treated sol muscles. The lower basal 
glucose uptake in dex treated groups was not expected, as similar experiments have not 
found lower basal glucose uptake in dex treated versus saline treated groups to this extent 
[34, 36, 49, 58]. Dimitriadis  et al. did find this after 5 days dex treatment, however [42]. It 
must also be noted that the basal glucose uptake found in Experiment I was higher than 
what has been found in previous experiments at STAMI.  
Dex treatment led to lower insulin stimulated glucose uptake in both epi and sol              
The decrease in insulin stimulated glucose uptake at supraphysiological concentration from 
day 1 to day 5 was ≈40 and ≈55 % in saline and dex treated epi respectively. The decrease in 
insulin stimulated glucose uptake at physiological concentration from day 1 to 5 was ≈25 and 
≈35 % in saline and dex treated sol respectively. The decrease in the supraphysiological 
group was ≈25 and ≈40 % in saline and dex treated sol respectively.  The higher reduction in 
insulin-stimulated glucose uptake in dex than in saline treated muscles from day 1 to 5 
suggests an onset of insulin insensitivity.  
Data from experiment I is in agreement with other studies showing impaired glucose uptake 
due to dex treatment during the same time, in a similar manner [34, 36, 49, 58]. Holmäng et 
al. discuss the effect of dex treatment as stepwise, where impairment of the glycogen 
synthesis system is first impaired in insulin-sensitive muscles by acute dex treatment. The 
rest of the muscles, as well as an impairment of glucose uptake is, however, evident after 
two days treatment [59].  
The department at STAMI has not previously experimented with 5 days dex treatment, 
though other research groups have. Dimitriadis et al. showed impairment of insulin-
mediated glucose uptake in physiological, but not at supraphysiological, insulin levels in sol 
after 12 hours fasting and 5 days treatment [42]. Dimitriadis et al. showed this, though using 
a higher dose of dex (0.5 mg/rat per day – rats 160-180 g) [42]. This strongly supports the 
findings in Experiment I that suggests that the impaired insulin sensitivity is correct.  
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Dex reduces insulin sensitivity in various tissues in the span of 5 days treatment 
The impaired glucose uptake and the impaired phosphorylation of important steps within 
the insulin signaling cascade suggest onset of insulin insensitivity after 5 days of dex 
treatment. Due to PKB’s effect on translocation of GLUT4, decreased phosphorylation of PKB 
will support the findings that glucose uptake is decreased [36]. This seems to coincide with 
our experiment, as the dex treated rats had a decreased glucose uptake as well as reduced 
insulin-stimulated PKB phosphorylation at both Ser473 and Thr308. 
The lack of significant differences between quite large differences in dex and saline treated 
rats might indicate too few rats in each group (n=3-4). There is no reason to believe that 
weight difference between saline and dex treated rats is too large.  
5.6 Experiment II 
Experiment II was set up to investigate the effects of 11 day dex treatment, and compare 
this to 1 day of treatment, as well as how fasting status affected the results.  
5.7 Rat and muscle weight and ratios 
Dex treatment led to acute drop in food intake, body and muscle weight retardation     
The weight retardation in the dex treated rats follow the same pattern as seen in Experiment 
I; though the dex treated rats lost weight in the period from day 1 to 11. At the end of the 11 
day period saline treated rats had gained ≈ 35 % while dex treated had lost ≈ 15 % of their 
own weight on day 1.  
We measured food-intake as well in this experiment, and saw a 40 % drop in food intake 
after the first dex injection, saline treated rats showed no change in food intake. In the dex 
treated group average food intake plummeted from ≈20-25 grams per rat daily initially to 
≈15 and ≈12 on the two days following dex injection. The daily food intake per rat stabilized 
at ≈15 g per rat from day 3 and onwards. `Food intake:100 g body weight´-ratio showed that 
dex treated rats ate less from day 3 to 6 after injection while saline treated rats remained on 
the same ratio level. When related to the `food intake:100 g body weight´-ratio the dex 
treated rats catched up with the saline treated rats on day 6 and remained similar from this 
day on. This indicates an acute drop in food intake as a result of dex treatment, then 
normalization after 6 days. He et al. [60] did not report of a sudden drop in food intake, but 
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rather that dex ate less than saline treated rats (male 15% less, females 45 % less on day 35), 
but did not show a lower `food intake:100 g body weight´ ratio compared to saline treated 
rats. He et al. used dex administration from a very early age (0.2 mg/kg from 2 days of age) 
in Sprague Dawley rats in a period from 2 to 120 days of age.  
The `muscle weight:rat weight´ differ slightly between the different groups, hence indicating 
one or both factors to have changed. Ratios between saline and dex treated rats are equal 
on day 1. Dex treated ratios are 0.01 higher than saline treated in both the fed and fasted 
group on day 11. This is not a result of the decreased EDL weight, but rather a sign of a 
higher decrease in body weight than the decrease in muscle weight. EDL weight differ 
between dex and saline treated rats; the EDL from dex treated rats weighed an average of 
31 mg on day 11, compared to the EDL from saline treated rats weighing an average of 50 
mg the same day. This might affect the rates of diffusion in to the muscle during incubation; 
probably affecting some of the measurements (e.g. glucose uptake) as the surface areas are 
approximately equal in saline and dex treated muscles, though weight and thickness differ. 
Dimitriadis et al. discuss the  higher rates of proteolysis in dex treated muscles than saline 
treated muscles [42], and this might be one of many explanations for the weight decrease.   
5.8 Glycogen content 
5.8.1 Glycogen content in skeletal muscles 
Dex treatment impairs glycogenolysis initiated by fasting compared to saline treatment            
Fasting initiate processes that liberate energy, glycogenolysis is one of these, and is said to 
be one of the most important processes to redistribute energy. As skeletal muscles contain 
80 % of the body’s carbohydrates, this redistribution is often necessary, lactate from 
glycogenolysis is thought to play a key role [24].  
Fasting decreased glycogen content in all saline treated groups, but to different extent 
depending on incubation buffer as discussed in the following paragraphs. There is though 
some general conclusions to be drawn from the fed versus fasted data. Fasting decrease 
glycogen levels in basal, insulin and adrenaline buffers, glycogen content in contracted 
muscles on the other hand is not affected by fasting status and is reduced to the same levels 
as in fed status. Glycogen content in dex treated rats is not decreased to the same degree as 
glycogen content in saline treated rats.  
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Coderre et al. showed that dex treatment abolished the decrease in glycogen content as a 
response to fasting, leading to higher glycogen content in dex treated muscles when fasted 
which support our data [58, 61]. However, our data show higher glycogen content in dex 
treated rats in the fed status as well, ≈20 % higher on day 1 and ≈30 % higher on day 11 
across all groups. The elevated glycogen content in dex treated EDLs are similar to the 
findings in Experiment I in both epi and sol. Coderre et al. showed that glycogen content did 
not differ between saline and dex treated sol when rats were in a fed state [58, 61]. There is, 
however, a tendency in Coderre et al.’s data of higher glycogen content in all dex treated 
groups compared to saline treated groups, and might relate to the dosage dex administered 
(0.4 mg/kg for 14 days). Coderre et al. reports that the higher glycogen contents found in 
dex treated rats possibly is a result of impaired fasting-induced glycogenolysis than glycogen 
supercompensation [26]. Data from Experiment II, and data from others, suggest a mix of 
these two as fed dex treated rats also have higher glycogen content than fed saline treated 
rats. Coderre et al. compared one group receiving dex to a group receiving both dex and 10 
% sucrose solution and found that glycogen content dropped to the same level during fasting 
as in saline treated rats. Thus dex may generate various effects on glycogen metabolism 
depending on physiological conditions [26].  
Dex treatment led to higher glycogen content in all groups compared to saline treatment 
Dex treated rats had basal glycogen content 23 % higher than the saline treated rats, 
regardless of length of treatment and fasting status. Experiment II found glycogen content in 
resting saline treated wEDL to be ≈200 mmol/kg, while dex treated glycogen content was 
≈240 mmol/kg. This increased glycogen level in dex treated rats is found in experiments 
done at STAMI previously [27, 36]. Coderre et al. discuss in several publications how dex 
does not lead to increased glycogen levels in skeletal muscles compared to saline in a fed 
state [26, 58], however, tendencies in Coderre et al’s data show higher glycogen levels in dex 
than saline treated rats in the fed state as well.  
Insulin did not prevent glycogenolysis during fasting, nor increase glycogen levels when fed 
Insulin incubation did not prevent glycogen breakdown due to fasting in any of the groups, 
nor did insulin incubation increase glycogen content in any of the rEDL compared to basal 
glycogen content in the wEDL. The effect of higher glycogen breakdown in saline treated 
muscles than in dex treated muscles is probably not linked to the anabolic effect of insulin. 
66 
 
This is shown as fed muscles did not increase glycogen content while incubated in insulin 
compared to basal glycogen levels; thus effect of sustained glycogen levels in fasted dex 
treated muscles are probably due to impaired glycogenolysis by dex treatment. There is no 
change in insulin-incubated glycogen content between day 1 and 11. Insulin has previously 
showed to increase glycogen content slightly in saline treated muscles, this equals ≈9 % 
increase in epi and ≈6 % in sol [43]. This higher glycogen content is too small to be of 
significance, though this is supported by REF . There are some discrepancies between the 
methods used, Aslesen et al. uses 30 minutes incubation, as well as different muscles.  
Dex treatment decreased adrenaline-mediated glycogenolysis     
Adrenaline incubation decreased glycogen content to lower levels than basal glycogen 
content in all groups. Fasting status reduced the adrenaline-mediated glycogenolysis further 
in saline than dex treated groups. Peters et al. found decreased glycogen levels in 
adrenaline-treated epi, but not sol [62], this is reflected by Jensen et al. that found 
adrenaline stimulated glycogenolysis to be reduced in EDL, but not in soleus [63]. Jensen et 
al. discuss the β2-adrenoceptor density as twice as high in type I muscles, and the paradox 
that these muscles are shown to have a lower rate of glycogenolysis when influenced by 
adrenaline. Aslesen et al. found adrenaline-mediated glycogenolysis equaling ≈15 % in epi 
and ≈20 % reduction from basal glycogen content in the fed state [43].  
Contraction reduced glycogen content in dex and saline treated muscles equally 
Glycogenolysis as a result of contraction is a well-known effect. Contraction mediates 
decrease in glycogen levels in Experiment II to the same degree in all muscles, regardless of 
fasting status and whether dex or saline treatment was given. Even though glycogen content 
in basal dex treated groups are higher, contraction reduces glycogen contents to the same 
extent. Contraction also reduces glycogen content to almost equal levels; ≈95 and ≈75 
mmol/kg in dex and saline treated muscles respectively. Basal glycogen content in wEDL is 
roughly two-fold to glycogen content found in contracted groups from rEDL. This reduction 
in glycogen content due to contraction is verified by Ruzzin et al. in sol and epi muscles. The 
authors show a significantly higher glycogen content in dex than in saline treated rats after 
contraction. Ruzzin et al.’s experiment did not completely fast the rats as discussed earlier, 
and contracted the muscles for 30 minutes [49]. The fact that contraction was performed for 
60 minutes in Experiment II could be the reason for the equal glycogen contents found in 
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saline and dex treated groups. Ruzzin et al. authors further suggest that epi muscles had a 
similar contraction-mediated glucose uptake in dex and saline treated muscles, yet higher 
glycogen content in dex treated after contraction (≈50 % higher in dex versus saline treated 
rats). The effects seen in epi were somewhat different from those found in sol, which 
showed equal glycogen content in dex and saline treated muscles after contraction [49]. 
Aslesen et al. showed contraction-stimulated glycogen reduction in saline treated rats 
equaling ≈47 and ≈37 % in epi and sol muscles respectively, the level of decrease is therefore 
similar to what is found in Experiment II.  
5.8.2 Glycogen content in liver 
Dex treatment completely abolish the liver glycogenolysis expected when fasted 
Experiment I did not compare liver glycogen content in fed rats to fasted rats. Experiment II 
on the other hand explores the effect of fasting status as well as dex and saline treatment on 
liver glycogen content. The findings from the fasted rats coincide with the findings from 
Experiment I; liver glycogen storages are completely depleted in saline treated rats, but 
sustains elevated in dex treated rats even after a 24 hour fast (p<0.0005). Surprisingly 
Experiment II found no higher liver glycogen content in the fed state in dex compared to the 
fed state in saline treated rats. Liver glycogen content in fed dex treated rats was even found 
to be lower than in fed saline treated rats (borderline significantly lower on day 11, p<0.12). 
This suggests impairment in fasting mediated glycogenolysis in liver due to dex treatment. 
Bruce et al. found 35 % higher liver glycogen content in obese Zucker rats than in lean Zucker 
rats [64], and nearly depletion after exercise in the lean phenotype, while only 50 % 
reduction in liver glycogen in the obese. Glycogenolysis in liver from obese Zucker rats seems 
impaired compared to the lean phenotype, this further supports the data from Experiment 
II.  
5.9 Lactate release 
Dex treatment increased lactate release                  
Lactate release is an important response to many factors and is crucial in the interchange of 
energy between tissues [24].  
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Dex treatment increased the basal lactate release compared to the saline treated group. This 
is evident in the adrenaline and contracted muscles as well, and a tendency of slightly 
increased insulin stimulated lactate release can be seen as well.  
Dimitriadis et al. used similar methods as in Experiment II to compare lactate release from 
sol muscle in dex treated rats (0.5 mg/rat daily, rat weight 160 g, for 5 days) [42]. Basal 
lactate release (1 µU/ml insulin) in the saline treated group was ≈10 mmol/kg, while the dex 
treated group released ≈ 12 mmol/kg. The insulin-stimulated lactate release (10,000 µU/ml) 
equaled ≈16 and ≈18 mmol/kg in the saline and dex treated groups respectively. These 
findings are somewhat similar to what was found in Experiment II, even though there are 
some discrepancies in methods; the higher dex dose, 12 hour fast, 1mM pyruvate in the 
buffer and the use of sol. The same research group has previous shown a two-fold increase 
in insulin-stimulated lactate release (10,000 µU/ml) in saline treated rats compared to basal 
lactate release (1 µU/ml); ≈15 versus ≈7 mmol/kg respectively) [65]. 
Bonen et al. has measured lactate content in both sol and EDL, and found higher 
concentrations of lactate in EDL than in sol [66], which support that our findings in EDL really 
are higher than Dimitriafis et al.’s findings in sol. 
 Dimitriadis et al. found reduced glucose transport and glucose phosphorylation in dex 
treated rats, and hypothesized that the rate through glycolysis would be decreased as well. 
This was, however, contradicted by the levels of lactate release that were normal. 
Dimitriadis et al. showed a decrease in the rate of glycogen synthesis and hypothesized that 
this might have lead to a shift of glucose metabolism towards glycolysis and increased 
lactate release [42].   
Fasting increased the adrenaline mediated lactate release            
Adrenaline increased lactate release with a mean of ≈ 70 % across all groups when compared 
to basal lactate release. Fasting increased the adrenaline-mediated lactate release. This was 
not seen in any other incubation medium, as basal, insulin and contraction-stimulated 
lactate release were decreased in fasted groups. Adrenaline is known to stimulate glycogen 
breakdown, hence increasing lactate release from skeletal muscles [43], adrenaline is, 
however, known to only increase glycolysis from glycogen, while lactate formation from 
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external glucose remains unchanged. This is probably through adrenaline-mediated increase 
in glucose 6-phosphate which blocks hexokinase, thus blocking glucose phosphorylation [43]. 
Aslesen et al. showed that lactate concentration in a muscle incubated in adrenaline in a fed 
state led to a 2-3-fold increase in sol and epi muscles, insulin increased lactate release by 
≈30-40 %, while contraction increased lactate concentration 10-fold [43]. Notice that these 
results were achieved from muscle tissue and not incubation buffer, hence following 
different methods than Experiment II. The relative increase is however interesting, at least 
when considering the fact that most lactate is transported out of the cells and is transferable 
to our results.   
Incremental lactate release has been studied by Leighton et al. [67] and Chaliss et al. [68]. 
The method used is based on the incorporation of U-14C-glucose into lactate, the authors 
uses this as a direct method of measuring glycolysis from glucose uptake in the muscle. 
Chaliss et al. also used methods measuring lactate concentration in muscle tissue.  
Contraction increased lactate release                              
The three-fold contraction-mediated increase in lactate release from basal lactate release is 
supported by other publications. G. Van Hall discusses the contraction mediated increase in 
lactate release, however, 14C-lactate uptake in skeletal muscles was increased several-fold, 
hence no net flow of lactate in and out of the muscles [69]. This support our data of 
increased glycogenolysis in dex treated rats as levels of lactate release are increased, in 
concert with initially increased glycogen content in the dex treated group and a possible dex-
mediated impairment of GS activation as presented later. G. Van Hall discuss a contraction 
studies that has seen that light exercise in one hind limb led to increased lactate uptake, 
while a hind leg in rest led to increased lactate production [69]. Our results does not 
measure lactate uptake in the incubated muscles, but increased lactate release is definitely 
evident in our studies. 
5.10 Western blots 
Dex treatment impaired insulin-stimulated PKB Ser473 phosphorylation     
Contraction-stimulated PKB Ser473 phosphorylation was low compared to insulin stimulated 
phosphorylation levels (≈12 %), this coincides with other published articles [36, 49, 52].  
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Dex treated groups had a lower insulin-stimulated level of PKB Ser473 phosphorylation than 
saline treated groups. This is supported by Experiment I,  as well as Burén et al. [34], and 
Ruzzin et al. in epi and sol muscles [49]. Burén et al. showed that dex treatment impaired 
insulin-stimulated PKB Ser473 phosphorylation both when incubated in insulin at 
physiological and supraphysiological concentrations.  
Fasting seems to increase insulin stimulated levels of PKB Ser473 phosphorylation in the dex 
and saline treated groups, though to a higher degree in dex treated groups. Other 
publications have shown a more certain decrease in PKB Ser473 phosphorylation as a 
response to fasting, and contradicts the findings in Experiment II. Two separate publications 
by Lai et al. and Jensen et al. showed 24 hours fasted saline treated rats to have a two-fold 
higher level of PKB Ser473 phosphorylation versus fed rats [28, 29]. Ruzzin et al. showed 
lower insulin-stimulated PKB phosphorylation in dex than saline treated groups at both 
Ser473 and Thr308 residues and supports the impaired insulin-activated PKB phosphorylation 
in dex treated rats [36, 49].  
Dex mediate insulin resistance, this is evident in part through insulin’s decreased ability to 
phosphorylate PKB Ser473.  
Experiment II was unable to show that dex treatment impairs insulin-stimulated GSK-3β 
Ser9 phosphorylation                 
Experiment II show equal levels of insulin-stimulated GSK-3β Ser9 phosphorylation on day 1. 
However, an increase in the dex treated insulin-stimulated GSK-3β Ser9 phosphorylation on 
day 11 compared to saline treated leads to ≈15 % higher levels in the fed, and 40 % higher in 
the fasted group (p<0.02). Burén et al. showed that dex decreased insulin-stimulated GSK-3β 
Ser9 phosphorylation in dex compared to saline treated rats [34]. Ruzzin et al., however, was 
not capable to show impaired insulin-stimulated GSK-3β Ser9 or GSK-3α Ser21 
phosphorylation in epi, but did so in sol [49]. The results from GSK-3 phosphorylation is 
found not to coincide with the impaired insulin-stimulated PKB Ser473 phosphorylation in epi 
muscles as presented above [49], and might suggest fiber-type specific differences.  
Contraction led to GSK-3β Ser9 dephosphorylation to same extent in dex as saline treated 
Contraction mediated dephosphorylation of GSK-3β Ser9 to the same extent in both dex and 
saline treated muscles (≈50-60 % in both dex and saline). This was also found by Ruzzin et al. 
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in epi but not sol, in which the authors concluded that the degree of contraction mediated 
phosphorylation of GSK-3β Ser9 is fiber type specific and differed between sol and epi [49]. 
Epi had a higher level of contraction-mediated GSK-3β Ser9 phosphorylation at ≈70-80 % of 
insulin-mediated phosphorylation [49]. Sakamoto et al. showed contraction mediated GSK-
3β Ser9 phosphorylation to be ≈80 % of insulin-mediated phosphorylation [70].   
Dex treatment led to impairment in insulin-stimulated activation of GS Ser641          
Dex treatment impaired insulin stimulated GS Ser641 dephosphorylation on day 11, this was 
not seen at all in the saline treated rats, or on day 1 of dex treatment. This is similar results 
as Ruzzin et al. published [49], and suggests that insulin is unable to activate GS [28].  
Coderre et al. discuss the finding that dex treatment was associated with lower GS activity 
ratio, and concludes that an inhibition of fasting-induced glycogenolysis rather than glycogen 
supercompensation takes place [26]. This supports the findings in Experiment II of an 
impairment of insulin stimulated GS Ser641 activation. Lai et al. found that high glycogen 
increased GS Ser641 phosphorylation [30]. This might in part be explanation for the findings in 
Experiment II where dex treated groups had a higher degree of GS Ser641 phosphorylation, 
and coinciding higher glycogen content, another interesting finding by Lai et al was that 
contraction on the other hand activates GS independently of glycogen content.   
Contraction led to different degree of GS activation between dex and saline treatment 
Contracted muscles from saline treated rats showed reduced GS Ser641 phosphorylation to 
the equal levels to ≈80 % of the insulin stimulated phosphorylation on day 1. Contracted 
muscles from dex treated rats on day 1 showed the same level of dephosphorylation 
compared to saline treated muscles. Contracted muscles from dex treated rats on day 11 on 
the other hand showed impaired GS Ser641 dephosphorylation and were ≈50 and ≈25 % 
higher than the saline treated group in respectively fed and fasted status. Ruzzin et al. on the 
other hand found that contraction led to same levels of GS Ser641 phosphorylation in both 
dex and saline treated sol after 12 days treatment [49]. Lai et al. showed contraction-
mediated dephosphorylation of GS Ser641 to the same degree as Ruzzin et al. in previous 
experiments in both fed and fasted saline treated rats [30]. 
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5.11 Glucose uptake 
Contraction stimulated glucose uptake to the same extent in dex as saline treated rats    
Glucose uptake is regulated by several factors, contraction is one strong mediator to 
increase glucose uptake. Dex treatment led to similar contraction-stimulated glucose uptake 
compared to saline treatment on day 1. Dex treated muscles had a higher contraction-
stimulated glucose uptake on day 11 than saline treated groups though. Several articles 
show that contraction leads to normal glucose uptake in otherwise insulin-resistant muscles 
from dex treated rats [49]. The reason why dex treatment showed significantly higher insulin 
stimulated glucose uptake on day 11 can theoretically be connected to the mounting of 
muscles, giving uneven degree of contraction for instance. This is, however, not plausible 
due to the high number of muscles incubated (n=7) as well as the experience of the one 
mounting the muscles. However, the weight of the EDLs was higher in the saline treated 
group and glucose uptake per muscle wet weight will be lower due to a lower 
`surface:weight´ ratio compared to the smaller dex treated EDLs. There is also the possibility 
of insulin insensitivity in the saline treated rats as they weigh significantly more than dex 
treated rats. Other publications, to the best of my knowledge, uses 30 minutes contraction 
when measuring glucose uptake instead of the 60 minutes used in Experiment II. This will 
affect glucose uptake. PATHWAY 
Insulin stimulated glucose uptake to the same extent in dex as saline treated rats      
Dex treatment is known to impair insulin-stimulated glucose uptake in skeletal muscles, and 
there are presented several reasons for this in literature. Insulin acts mainly on glucose 
uptake through translocation of the GLUT4 transporters [34, 36, 40, 42] and it is through this 
insulin-activated pathway one believe dex exerts its effects on glucose uptake. GLUT4 
translocation is mediated through both contraction and insulin stimulation. Both 
hyperglycemia and hyperinsulinemia are seen spontaneous following dex administration, 
over time this result in insulin resistance – increased glycogen storage is also seen, possibly a 
response to the increased levels of insulin.  
Burén et al. describes that dex treatment resulted in lower insulin-stimulated glucose uptake 
than saline treatment in both sol and epi after 11 days treatment (equaling ≈40 and ≈30 % at 
physiological and ≈30 and ≈20 % at supraphysiological insulin levels in the respective 
muscles during 30 minutes of incubation) [34]. Experiment II used 60 minutes of incubation, 
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this can affect glucose uptake severely. This can be reflected in the insulin-stimulated 
glucose uptake that is equal in dex and saline treated rats on all days.  
Adrenaline led to lower glucose uptake compared to basal glucose uptake   
Experiment II show that adrenaline inhibit glucose uptake compared to the basal glucose 
uptake. A ≈40 and ≈20 % reduction in glucose uptake is seen from basal levels in the fed and 
fasted groups respectively. Inhibition of glucose uptake by adrenaline may be caused by 
reduction of intrinsic activity of the glucose transporter by phosphorylation or indirectly by 
accumulation of free glucose [25]. Jensen et al. argues that adrenaline might inhibit glucose 
uptake directly; GLUT4 is translocated during insulin stimulation, GLUT4 can however be 
phosphorylated by β–adrenergic receptor stimulation [25]. The decrease in glucose uptake 
described by Jensen et al. may then be explained by loss of intrinsic activity of the GLUT4 
transporter.  
Dex failed to show impaired insulin-stimulated glucose uptake, which does not orchestrate 
the impaired insulin-mediated modulation of the insulin signaling pathway      
Glucose uptake is not altered by dex treatment for 11 days in Experiment II, though 
impairment of insulin actions in the insulin pathway downstream of IR is obvious. Dex, as a 
steroid hormone affecting nuclear receptors, induces changes in protein expression. These 
processes develops over time and might be the reason for the various findings concerning 
expression of GS, PKB α/β, GSK-3 α/β and GLUT4 in dex compared to saline treated rats. 
Ruzzin et al. did not find any differences in expression of GS, PKB α/β, GSK-3 α/β between 
saline and dex treated rats, nor in GLUT4 expression in sol, but higher in dex treated epi [36]. 
The results of unaltered GLUT4 expression in sol has been shown earlier [42], but is 
contradicted by Coderre et al. [40]. Burén et al.(2008) contradicts the latter experiment 
when reporting a reduction of PKB expression in dex treated sol and epi (≈50 and 40 % 
reduction compared to saline treated muscles), but supports the increase in GLUT4 
expression in both sol and epi that match the publication by Ruzzin et al.(≈30 and 70 % 
increase compared to saline treated muscles) [34]. Burén et al. (2002) showed, contradictory 
to the findings in 2008, that dex decreased PI 3-K and PKB content in rat adipocytes after 
long-term treatment [41]. These contradictory findings make certain conclusions regarding 
changes in expression downstream of IR as a response to dex treatment difficult. The higher 
GLUT4 expression as a response to dex treatment is ascertained, but seems odd compared 
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to the lower glucose uptake in the dex treated muscles. The paradox can be explained by the 
atrophy experienced by dex treatment, hence concentrating the proteins in the muscle as 
Ruzzin et al. discusses [36]. The muscle atrophy seen in Experiment II is, however, of bigger 
magnitude than is seen in other studies. Et al. report of reduction in dex treated skeletal 
muscle weight equaling 10 % of saline treated muscle weight.  
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6 Conclusions 
6.1 Experiment I 
 
1) Glycogen content is notably higher in dex treated tissues compared to saline treated 
tissues after a 12 hour fast  
a. Glycogen content in skeletal muscle was escalated in all dex treated groups 
b. Liver glycogen was nearly depleted in saline treated rats, and was significantly 
higher in dex treated rats after only 1 day treatment. This effect carries 
through the 5 days of treatment 
c. Cardiac muscle glycogen content was higher in all dex treated groups on all 
days, but more evident when acutely administered 
2) Dex treatment reduces PKB phosphorylation at both site Ser473 and Thr308 notably 
compared to saline treatment 
3) Glucose uptake in dex treated rats show impaired insulin-stimulated glucose uptake 
compared to saline treated rats. This tendency is more evident in sol when incubated 
in insulin at physiological levels.  
 
 
Experiment I did show tendencies that dex induced insulin-resistance during 5 days 
treatment to a similar degree to what is found during longer treatment.   
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6.2 Experiment II 
 
1) Dex treatment induced both body and muscle weight retardation, and led to an 
instant cut in food intake that normalized after some days of dex treatment 
2) Glycogen content in dex treated rats was elevated in all groups compared to saline 
treated rats  
a. Glycogen content in dex treated rats was elevated in all groups compared to 
saline treated rats, neither adrenaline nor contraction managed to decrease 
glycogen content in dex treated muscles to the same extent as in saline 
treated muscles. Insulin-mediated glycogen increase was not seen in any of 
the muscles.  
b. Dex treatment impaired utilization of stored glycogen in liver when subjected 
to fast on both day 1 and 11 compared to saline treated rats, even though the 
liver glycogen content between saline and dex treated rats were equal in the 
fed state.  
3) Dex treatment increased lactate release in all muscles, in all incubation mediums. 
Neither adrenaline, insulin nor contraction managed to increase lactate release in 
saline treated muscles to similar levels as lactate release in dex treated muscles.  
4) Dex treatment significantly impaired insulin-stimulated PKB Ser473 phosphorylation in 
the fed status, however not in the fasted status. Dex treatment was not shown to 
affect insulin-stimulated GSK-3 Ser9 phosphorylation, except from on day 11 in the 
fasted rats, in which dex increased insulin-stimulated GSK-3 Ser9 phosphorylation. 
Dex increased phosphorylation of both insulin- and contraction-stimulated GS Ser641 
in all groups, but only significantly on day 11. 
5) Dex treatment failed to show impaired glucose uptake compared to saline treated 
rats. Also when mediators promoting glucose uptake were added; insulin, 
contraction and adrenaline.   
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Appendices 
Appendix 1 – WHO Summary of Technical Report and Recommendations [3] 
 
Since 1965 the World Health Organization (WHO) has published guidelines for the diagnosis and classification of diabetes. 
These were last reviewed in 1998 and were published as the guidelines for the Definition, Diagnosis and Classification of 
Diabetes Mellitus and its Complications. Since then more information relevant to the diagnosis of diabetes has become 
available. In November 2005 a joint WHO and International Diabetes Federation (IDF) Technical Advisory Group met in 
Geneva to review and update the current WHO guidelines.  
After consideration of available data and recent recommendations made by other organisations, the Group made the 
following recommendations: 
Recommendation 1 
The current WHO diagnostic criteria for diabetes should be maintained – fasting plasma glucose ≥ 7.0mmol/l (126mg/dl) or 
2–h plasma glucose ≥ 11.1mmol/l (200mg/dl).  
Despite the limitations with the data from which the diagnostic criteria for diabetes are derived, the current criteria 
distinguish a group with significantly increased premature mortality and increased risk of microvascular and cardiovascular 
complications. 
Recommendation 2 
Since there are insufficient data to accurately define normal glucose levels, the term ‘normoglycaemia’ should be used for 
glucose levels associated with low risk of developing diabetes or cardiovascular disease, that is levels below those used to 
define intermediate hyperglycaemia. 
Recommendation 3 
The current WHO definition for Impaired Glucose Tolerance (IGT) should be maintained for the present.  
Consideration should be given to replacing this category of intermediate hyperglycaemia by an overall risk assessment for 
diabetes, cardiovascular disease, or both, which includes a measure of glucose as a continuous variable. 
Recommendation 4 
The fasting plasma glucose cut-point for Impaired Fasting Glucose (IFG) should remain at 6.1mmol/l. 
This decision was based on concerns about the significant increase in IFG prevalence which would occur with lowering the 
cut-point and the impact on individuals and health systems. There is a lack of evidence of any benefit in terms of reducing 
adverse outcomes or progression to diabetes and people identified by a lower cut-point eg 5.6mmol/l (100mg/dl) have a 
more favourable cardiovascular risk profile and only half the risk of developing diabetes compared with those above the 
current WHO cutpoint. Lowering the cut-point would increase the proportion of people with IGT who also have IFG but 
decreases the proportion of people with IFG who also have IGT.  
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Consideration should be given to replacing this category of intermediate hyperglycemia by an overall risk assessment for 
diabetes, cardiovascular disease, or both, which includes a measure of glucose as a continuous variable. 
Recommendation 5 
1. Venous plasma glucose should be the standard method for measuring and reporting glucose concentrations in blood. 
However in recognition of the widespread use of capillary sampling, especially in under-resourced countries, conversion 
values for capillary plasma glucose are provided for post-load glucose values. Fasting values for venous and capillary plasma 
glucose are identical. 
2. Glucose should be measured immediately after collection by near-patient testing, or if a blood sample is collected, 
plasma should be immediately separated, or the sample should be collected into a container with glycolytic inhibitors and 
placed in ice-water until separated prior to analysis. 
Recommendation 6 
The oral glucose tolerance test (OGTT) should be retained as a diagnostic test for the following reasons: 
 fasting plasma glucose alone fails to diagnose approximately 30% of cases of previously undiagnosed diabetes, 
 fan OGTT is the only means of identifying people with IGT, 
 fan OGTT is frequently needed to confirm or exclude an abnormality of glucose tolerance in asymptomatic 
people. 
An OGTT should be used in individuals with fasting plasma glucose 6.1–6.9mmol/l (110–125mg/dl) to determine glucose 
tolerance status. 
Recommendation 7 
Currently HbA1c is not considered a suitable diagnostic test for diabetes or intermediate hyperglycemia. 
The following Table summarises the 2006 WHO recommendations for the diagnostic criteria for diabetes and intermediate 
hyperglycemia. 
Diabetes 
Fasting plasma glucose   ≥7.0mmol/l (126mg/dl) 
2–h plasma glucose*   or 
≥11.1mmol/l (200mg/dl) 
Impaired Glucose Tolerance (IGT) 
Fasting plasma glucose   <7.0mmol/l (126mg/dl) 
2–h plasma glucose*   and 
≥7.8 and <11.1mmol/l 
(140mg/dl and 200mg/dl) 
Impaired Fasting Glucose (IFG) 
Fasting plasma glucose   6.1 to 6.9mmol/l 
2–h plasma glucose*   (110mg/dl to 125mg/dl) 
     and (if measured) 
<7.8mmol/l (140mg/dl) 
* Venous plasma glucose 2–h after ingestion of 75g oral glucose load 
* If 2–h plasma glucose is not measured, status is uncertain as diabetes or IGT cannot be excluded 
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Appendix 2 – Time-course experiment I 
 
Time-course for dexamethasone-induced insulin resistance: glucose uptake. 
Jørgen Jensen, Ada Ingvaldsen, Fang-Chin Lin, Anders Rasmushaugen; 2008-07-02 
Experiment: 3.-8. August 2008 
 
32 rats of 90-100 g will arrive Wednesday 23. of July 
32 rats (16 dex and 16 control). Rats live 2 per cage. 
Weigh rats and food intake every day at 10 AM 
 
Rat weight when dex injection is started ~180 g. 
Dex:   I.p. injection (1.0 mg/kg) 
Control: I.p. injection of saline (1.0 ml/kg) 
 
Injection of dex between 10-11 h from Sunday 3.8 to Thursday 7.8. 
Dex: 0.1 mg/ml saline. Inject 1 ml/100g rat. 
(Dexamethasone solubility: 10 mg/100 ml (0.1 mg/ml) 25 ºC.) 
Make new solution every 2nd day (min. 10 ml daily). Store in refrigerator 
 
Experiments:  
Monday 4.8., Tuesday 5.8., Wednesday 6.8. and Friday 8.8. Rats are fasted 12 h before 
experiment (from 22.00 h) 
Each day: 4 dex and 4 saline treated rats.   
 
Insulin-stimulated glucose uptake measured in epitrochlearis (0 and 10 mU/ml incubation) 
Insulin-stimulated glucose uptake measured in soleus muscles (0, 0.02 and 10 mU/ml 
incubation) 
Blood samples for analysis of insulin and cytokines.  
(⅓ muscle for glucose uptake and glycogen content, ⅓ for Western Blot and ⅓ for glycogen 
synthase activity). 
 
Weigh epididymal fat and heart. 
 
Freeze soleus and epi, liver, heart, epididymal fat. 
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Appendix 3 – Time-course experiment II 
Time-course for dexamethasone-induced insulin resistance: glucose uptake. 
Jørgen Jensen, Anders Rasmushaugen, Ada Ingvaldsen, Jorid Thrane Stuenæs and Fang-
Chin Lin 
 
Purpose: The purpose of this trial is to examine the effect of dex acutely administered versus 
an 11-day administration; these rats will be compared with control groups as well. We will in 
addition compare the difference between fasted and fed rats for both groups (24 hour 
fasting).  
 
Experiment: As soon as the two groups reach ~150 g, (Experiment A9 16th and experiment 
A10 17th of February). Experiment can be postponed if significantly lower weight than 150g.  
 
16 rats of 85-95 g will arrive at 4th of February,  
16 rats (8 dex and 8 controls). Rats live 2 per cage  
 
Between 10-11 AM: Inject dex and weigh rats and food intake 
 
Dex/saline injection starts the day prior to experiment Monday 16th of February for 8 rats 
(Experiment A9). 
Dex/saline injection starts the day prior to experiment Tuesday 17th of February (Experiment 
A10). 
 
Dex:   I.p. injection of 1,0 mg/kg.  
Control:  I.p. injection of saline 1.0 ml/kg. 
 
Dex: 0.1 mg/ml saline. Inject 1 ml/100 g rat. 
(Dex solubility: 10 mg/100 ml (0.1 mg/ml) – 25 ºC.) 
Make new solution every 2nd day (min. 10 ml daily). Store in refrigerator.  
 
Experiments:  
Monday 16th: 1 day dexinjection (8 rats: 4 dex and 4 controls) 
2 dex treated rats are fasted 24 h before experiment (from 10.00 h), the other 2 rats are 
given normal access to chow until experiment the following day.  
2 Control rats fasted and 2 are given normal access to chow. 
 
Tuesday 17th: 1 day dexinjection (8 rats: 4 dex and 4 controls)  
2 dex treated rats are fasted 24 h before experiment (from 10.00 h), the other 2 rats are 
given normal access to chow until experiment the following day.  
2 Control rats fasted and 2 are given normal access to chow. 
 
Liver, heart, red and white gastro, epididymal fat, brain, Epi, EDL and Soleus are collected for 
measurement of glucose uptake, glycogen content, glycogen synthesis and buffer is 
measured for lactate.  
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Appendix 4 - Chemicals and equipment 
Other chemicals not mentioned here are all from Merck or Sigma-Aldrich.  
Name of product/equipment Serial number Producer 
Actrapid Injection solution 100 IE/ml 014398 Novo Nordisk A/S, Dk 
Immobilon Western 
Chemiluminescent HRP Substrate 
WBKLS0500 Millipore 
Immobilon-P Transfer membrane, 
PVDF 
IPVH00010 Millipore 
Pony Vial 6000292 PerkinElmer 
Prestained precision protein 
standards 
161-0373 BioRad 
Antibody GS Ser641 Cell signaling Tech. #3891  
Antibody GSK Total protein Upstate #05-412 MedProbe 
Antibody p-GSK-3α/β Ser21/9 #9331 Cell Signaling Tech. Inc 
Antibody PKB Ser473 #9271 Cell Signaling Tech. Inc. 
Antibody PKB Thr308 #4056 Cell Signaling Tech. Inc. 
Protease inhibitor cocktail P-8340 Sigma-Aldrich 
Secondary antibody Anti-mouse Upstate #12-349 MedProbe 
Secondary antibody Anti-rabbit Cell signaling Tech. #7074 MedProbe 
Lactate dehydrogenase (LDH) L-2625 Sigma-Aldrich 
Equipment 
Muscle incubation equipment Made at STAMI  
Homogenizator Polytron PT1200 
Electrophoresis and blotting equipment BioRad 
Scintillation counter, TRI-Carb 1900 TR Packard 
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Appendix 5- solutions used in experiments 
BUFFER FOR MUSCLE INCUBATION, Krebs-Henseleit buffer: 
Stock I Concentration 
NaCL 1.16 M 
KCl 0.046 M 
KH2PO4 0.0116 M 
NaHCO3 0.253 M 
In H2Omillipore 
Stock II Concentration 
CaCl2x2H2O 0.025 M 
MgSO4x7H2O 0.0116 M 
In H2Omillipore 
 
 
 
Ready to-use solution is made daily: 
100 ml Stock I + 100 ml Stock II + 800 ml H2Omillipore 
The solution is gassed in 95 % O2/5 % CO2 for at least 45 minutes prior to use 
100 ml was taken out after gassing to use for lubricant while dissecting muscles, the 900 ml 
left was added:  
Substance Concentration 
BSA 0.1 % 
HEPES 5 mM 
Glucose monohydrate 5.5 mM 
Pyruvate 2 mM 
pH adjusted to 7.4 with NaOH if needed. 
 
GLYCOGEN CONTENT, Reaction solution: 
Concentrations 
Concentration of 
reagents 
Concentration 
Tris/HCl pH 8.1 100 mM 
MgCl2 1 mM 
Dithiothreitol, DTT 0.5 mM 
ATP 300 µM 
NADP+ 30 µM 
G6PDH 0.08 U/ml 
H2O millipore  
 
LACTATE RELEASE, Reaction solution 
Concentrations 
Concentration of 
reagents 
Concentration 
2a-2m-1p pH 9.9-10.0 50 mM 
L-Glutamate 2 mM 
NAD+ 500 µM 
LDH 10 U/ml 
GPT 3 U/ml 
H2O millipore  
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WESTERN BLOTTING, SDS-PAGE: 
Homogenization buffer Concentration in solution 
H2O millipore  
1 M HEPES pH 7.4 50 mM 
3 M NaCl 150 mM 
100 mM Na4P2O7 10 mM 
500 mM NaF 30 mM 
100 mM Na3VO4 1 mM 
200 mM EDTA 10 mM 
250 mM Benzamidin 2.5 mM 
Protease inhibitor cocktail (Sigma, P-8340) 0.5 µl/10 mg muscle 
Triton X-100* 1 % 
*(added directly after homogenization) 
5xSDS sample buffer Concentration in solution 
1.5 M Tris pH 6.8 313 mM 
20 % SDS 10 % 
2.5 % Bromphenol blue/glycerol 0.25 %/9.9 % 
Glycerol 19 % 
 
Stacking gel, 4 % acrylamide, 4 gels Total amount 
H2O millipore 6.4 ml 
1.5 Tris pH 6.8 0.67 ml 
20 % SDS 40 µl 
40 % acrylamide/bis (37.5:1) 0.8 ml 
TEMED (BioRad, concentrated) 8  µl 
10 % Ammonium persulfate 80 µl 
 
Separation gel, 10 % acrylamide, 4 gels Total amount 
H2O millipore 7.8 ml 
1.5 Tris pH 8.8 4 ml 
20 % SDS 80 µl 
40 % acrylamide/bis (37.5:1) 4 ml 
TEMED (BioRad, concentrated) 9.6  µl 
10 % ammonium persulfate 160 µl 
 
Electrophoresis buffer Concentration 
Tris 25 mM 
Glycine 192 mM 
SDS 0.1 % 
In H2O Millipore 
 
Transfer buffer Concentration 
Tris 25 mM 
Glycine 192 mM 
Methanol 10 % 
In H2O Millipore 
 
PBS/0.1 % Tween 20 Concentration 
Na2HPO4 x 2H2O 80 mM 
NaH2PO4 x H2O 20 mM 
NaCl 100 mM 
Tween 20 0.1 % 
In H2O Millipore, pH-adjusted to 7.4 with NaOH.  
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Appendix 6 – method for Glycolytic flux measurement 
The radioactively labeled 0.25 µCi/ml 2-[3H] -glucose (30.6 Ci/mmol; NET 549 PerkinElmer) 
were added to the buffer (containing 5.5 mM glucose, 2mM pyruvate, 5 mM HEPES and 0.1 
% BSA). Used incubation buffer are frozen (-20 °C) as soon as possible. 750 µl H2Omillipore are 
added to scintillation tubes (Pony Vials 6000292, PerkinElmer) and an eppendorf vial without 
a lid is placed inside the scintillation tube, the eppendorf vial is filled with 5 µl HCl (to 
prevent microbial growth) and 50 µl of the sample buffer/blanks, 1 parallel are made for 
each sample. Before incubation in 37 °C for 3 days blanks are prepared. The blanks are 
divided in two groups; directly pipetted and incubated with the muscles (30 °C). The blanks 
incubated together with the muscles consist of 2 H2Omillipore parallels, 2 parallels of a solution 
with the same concentration radioactively labeled 2-[3H] -glucose as in the original buffer, 5 
µ HCl and 695 µl H2O. The blanks directly counted consist of 2 parallels of 745 µl H2Omillipore 
and 5 µl HCl, 2 parallels of a solution with the same concentration radioactively labeled 2-
[3H] -glucose as in the original buffer, 5 µ HCl and 695 µl H2O. 2 parallels of unused 
incubation buffer were also incubated. The eppendorf vials were placed within the 
scintillation tube with tweezers, it was important to avoid spilling of fluids between the 
compartments. The scintillation tube is closed and placed in 37 °C for a minimum of 72 hours 
– this will create equilibrium between the water in the eppendorf vial and the scintillation 
vial. After the incubation, the eppendorf vial was discarded and 4.5 ml Ultima Gold 
scintillation cocktail was added. The samples were counted for radioactivity (d.p.m.) on Tri-
Carb 1900 TR; 5 minutes counting, 2 cycles.  
Background for analysis of glycolytic flux; 
The method measures at what rate glucose is metabolized in the muscles incubated (rate of 
glycolysis). The buffer contains radioactive labeled glucose in known concentrations, as well 
is the glucose concentration in the buffer known (5 mM). Same kinetics are assumed 
between glucose and the radioactively labeled glucose. During metabolic processes in the 
muscle, 3H2O will be cleaved from the 2-[
3H] –glucose molecule. During equilibrium the 
amount 3H2O will, by calculating back to the original concentration in the small eppendorf 
vial, show the rate of glycolysis. 
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Appendix 7 – method for Glycogen synthesis measurement 
A measurement using either [14C(U)]-glucose or 2-[3H] -glucose (30.6 Ci/mmol; NET 549 
PerkinElmer) follows the same method.  
[14C(U)]-glucose was added to the incubation buffer, incubation time was 1 hour for the 
muscles. Muscles were handled as described earlier, 2-3 mg dw was used. Due to this, 
dissolving and preparation of the muscles follow the same steps as in method for 
measurement of glucose uptake, and the same blanks are prepared as mentioned. The point 
where this method deviates from the method for glucose uptake is after dissolving of the 
muscles; 500 µl of the digest was added to a saturated solution of 100 µl Na2SO4 and 100 µl 
glycogen solution (25 mg/ml – dissolved in H2Omillipore), then mixed thoroughly. 1.5 ml 
absolute ethanol stored at -70 °C was added to this solution (quick dispensing of the liquid 
from a pre-cooled pipette tip was important). Samples was precipitated overnight (-20 °C).  
The samples were centrifuged after precipitation at 3000 x g for 20 minutes at +4 °C, the 
supernatant was discarded. The precipitate was added 500 µl H2Omillipore and dissolved again 
(10 minutes, 70 °C). Samples were now re-precipitated with 1.0 ml absolute ethanol (-70 °C) 
and stored for at least 1 hour at -20 °C. Samples were mixed thoroughly at each step. The 
samples were centrifuged again after precipitation (3000 x g,  20 minutes,  +4 °C), 
supernatant was discarded. Tubes were placed upside-down on filter paper to remove 
excess solution for ca 5 minutes. The pellet was re-dissolved in 300 µl H2Omillipore (70 °C, 10 
minutes). Samples were cooled down, 250 µl of the solution was pipetted into counting vials 
(Pony Vial, Perkin Elmer) and added 3 ml Ultima Gold scintillation cocktail, thoroughly mixed. 
Samples were counted for radioactivity (d.p.m.) after 1 hour on Tri-Carb 1900 TR; 5 minutes 
counting, 2 cycles. The 4 vials containing incubation buffer from the day of experiment was 
counted again together with the samples.  
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Appendix 8 – List of experiments conducted with dex treatment 
 
 
 
